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Abstract 
Cancer is a pathology that affects a large portion of the world’s population [1]. It is an 
assembly of diseases with various symptoms that significantly decreases the patient’s life 
quality and has a high rate of mortality [2]. One of the most commonly used treatments for 
this pathology is chemotherapy, involving the use of combinations of drugs to kill cancer 
cells. Since these drugs either act directly on the membrane or have to cross it to reach their 
targets, the interactions between anticancer drugs and biological membranes are of high 
importance. 
The structure of biological membranes consists of a phospholipid bilayer. In healthy 
cells, phosphatidylcholine (PC) and phosphatidylserine (PS) are some of the most common 
lipids, the PS being found on the inner leaflet, but cancer cells’ membranes usually present 
higher heterogeneity in constitution, higher fluidity and the PS exposed to the extracellular 
media [3]. The complexity of the membrane and all the variables associated with the cells’ 
functions makes it a very difficult model to study. As such, artificial model membranes like 
liposomes might present a viable alternative, being a simpler and easier to manipulate 
model that accurately simulates the cell membrane’s constitution and behaviour. 
That being said, the aim of our study was to assess the effects of two anthracyclines used 
in chemotherapy, daunorubicin and doxorubicin, on the lipid membranes of four LUV 
formulation models, two of them constituted by dimyristoyl-phosphatidylcholine (DMPC) 
with and without cholesterol, mimicking the normal cell membrane, and the other two 
simulating the tumoral cell membrane, constituted of a mixture of dimyristoyl-
phosphatidylcholine (DMPC), dioloyl-phosphatidylcholine (DOPC) and dipalmitoyl-
phosphatidylserine (DPPS) at the proportions 3:1:1, respectively,  also with and without  
cholesterol. Hepes buffer at pH 7.4 and Tris buffer at pH 6.3 were used to mimic the normal 
and tumoral tissue’s pH, respectively. 
Dynamic Light Scattering (DLS) was used to determine liposome size and Electrophoretic 
Light Scattering (ELS) liposome zeta potential. The partition coefficient (Kp) of the drugs was 
determined through derivative spectroscopy using liposome/water sytems. Membrane 
location of daunorubicin involved spectrophotometry, spectrofluorimetry and lifetime 
fluorimetry measurements. Membrane fluidity and the effect of the two drugs on it were 
assessed through fluorescence anisotropy. 
 These techniques were employed on the four formulations of liposomes mentioned 
before. Membrane location and anisotropy techniques were also performed on tumoral cells, 
the cell line MDA-MB-231, to assess the ability of the designed models of mimicking the 
actual biomembranes. 
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Size measurements confirmed that the models were prepared as intended, with liposome 
sizes being close to 100 nm. Neither drug seemed to affect liposome size. Zeta potential 
confirmed that normal model membranes had a surface charge close to neutral and tumoral 
model membranes were slightly negatively charged, which is consistent with what happens 
naturally. Increase in drug concentration made the zeta potential in tumoral models less 
negative, meaning that the drug, positively charged, was interacting with the surface of 
these membrane models. 
Kp determination showed that the two drugs, although very similar, partition very 
differently. The highest Kp is found for the normal model. Partition for the two drugs 
decreases with the presence of cholesterol in the membrane for normal models, but the 
opposite occurs for the tumoral models. Doxorubicin partitions more than daunorubicin for 
all models except the tumoral with cholesterol model. 
Daunorubicin appears to localize between the acyl chains of phospholipids in the 
membrane but still interacting through electrostatic interactions with the polar heads, so it 
appears to locate at an intermediate region. 
In terms of fluidity, the normal model with cholesterol appears to be the most rigid of 
all and remains unchanged by the addition of the drugs tested, while the normal model is 
highly fluid. Contrarily to what was expected, the tumoral model with cholesterol becomes 
less fluid with the presence of drug, which does not happen in the tumoral model without 
cholesterol. 
Summarily, Kp values prove that there is interaction between both drugs and the four 
models studied. Both drugs partition significantly less into the normal model with 
cholesterol than the normal model without it. The opposite occurs in the tumoral models, 
where cholesterol seems to be causing some adjuvant effect on the partition of the drugs. 
Evidence suggests that the drug daunorubicin located at a more interfacial region, probably 
the cooperative zone. The tumoral model with cholesterol also seems to become more fluid 
at the physiological temperature for both drugs at the cooperative zone. Similar results 
were found for tumoral cells. From all the gathered information it can be hypothesized that 
cholesterol might be forming microdomains with some of the lipids of the tumoral model, 
increasing the rigidity of the membrane in certain areas but leaving the remaining areas 
permeable to the drug, hence the higher Kp values and higher overall fluidity. It could also 
be observed that the designed model membranes, although simple, replicated biomembranes 
quite well. This study and follow-up work can be a big step towards the validation of 
liposomes as models for cell membranes, and in the future allow the facilitation of drug-
membrane interaction studies. Possible future applications would involve not only the use in 
research but the introduction of the models at an industrial level for an easier, less 
expensive and quicker development of new drugs or delivery systems for the treatment of 
several diseases that are more efficient and possess fewer side effects. 
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Chapter 1  
 
Introduction 
Cancer is a pathology that affects a large portion of the world’s population. It affects 
people from any region regardless of culture or wealth and is one of the biggest causes of 
death. Over the last 35 years, the global burden of cancer has more than doubled, with 12.4 
million new cases diagnosed and 7.6 million cancer-related deaths just in 2008. With the 
continuous growth and aging of the world, predictions point towards about 27 million new 
cancer cases diagnosed and approximately 17 million deaths as a result of cancer in the year 
2030 [1].  
In the past, many of the greatest scientific and medical accomplishments were achieved 
in developed countries, resulting in higher exposure of the people to different kinds of 
radiation, radioactivity (from nuclear accidents, nuclear weapons…) and chemical 
carcinogens. Such events could explain why cancer was, in the past, a developed country 
disease [3-5]. However, in the current years, the trend was balanced out if not overturned, 
with at least half of the global cancer cases being found in low or medium resource countries. 
In fact, in 2008 five out of every ten diagnosed cancer cases occurred in these regions [6]. 
These countries are clearly more affected as the increase in cancer cases presents a far more 
complicated issue due to the lack of proper sanitary and health care conditions. In low to 
medium resource countries cancer treatment facilities and life-extending treatments are 
often unavailable for economic reasons [3]. 
According to the American Cancer Society, cancer is not a disease but encompasses a 
group of diseases that have in common the uncontrolled growth and spread of abnormal cells. 
It can cause virtually any sign or symptom depending on the tumor’s characteristics. The 
abnormal cells compete with the healthy cells for oxygen and nutrients, eventually leading to 
the death of healthy cells. If the spread of abnormal cells is not controlled, it can result in 
death [7-9]. 
There is still no definitive and 100% effective cure for cancer. There are, however, 
treatments with a high rate of success that can eradicate the disease from an individual [7]. 
One of these treatments, chemotherapy, involves the use of drugs to eliminate cancer cells 
through a variety of mechanisms. However, they act on all cells undergoing cellular division, 
so rapidly growing tissues like skin, liver or the intestinal tract, are also under the attack of 
these drugs, which leads to a number of undesirable and severe side effects that reduce the 
patients’ life quality throughout the treatment sometimes to a state of disability and can also 
interfere with the success of the treatment [5, 10] 
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The main targets of chemotherapeutic drugs are intracellular and therefore the drugs 
must be able to surpass the plasma and possibly the nuclear and organelle membranes. 
Therefore, the study of anticancer drug-membrane interactions is an important field of 
research since it provides understanding on the drugs’ pharmacology and pharmacokinetics 
[3]. The basic structure of all cell membranes is a curved lipid bilayer composed of various 
lipids which serves as a permeability barrier to the hydrophilic molecules on either side of it 
and host many peripheral and transmembrane proteins. As such, the biophysical properties of 
the lipids that compose the bilayer may modulate its behaviour in contact with drugs as well 
as the behaviour of associated proteins and other molecules. Therefore, it is important to 
study the effect of anticancer drugs on the membranes to evaluate their efficacy, but this 
may be complicated due to the high complexity of cells. Artificial lipid model membranes 
appear as a novel way to study drug-membrane interactions since they can be made of cell 
membrane components or derivatives and mimic its behaviour while the conditions involved 
are much easier to control [11]. 
1.1 - Cancer Ethiology and Pathophysiology 
1.1.1. Cancer Ethiology 
Cancer is a pathology that is characterized by the abnormal growth and development of 
cells that acquired new characteristics through genetic mutations that provide them with 
specific capabilities, such as the ability to proliferate independently of the mechanisms that 
regulate cellular growth [12, 13]. An agglomerate of abnormal cells is called a tumor or 
neoplasia and it is not necessarily malignant. A tumor becomes a cancer when its cells gain 
the ability to migrate through different tissues and therefore invade other regions of the 
organism [11, 14]. 
When in a tissue, the tumor cells compete with the normal cells for energy and nutrients. 
Since neoplastic cells have a higher growth ability, they have an advantage, and therefore 
inhibit the normal proliferation of healthy cells leading to the deterioration of the tissue and 
failure of its functions [15]. 
Tumors constitute complex tissues that include various different cell types which 
establish a number of heterotypic interactions in order to satisfy its necessities. A good 
example could be the process through which the tumor recruits regular cells to form tumor-
associated stroma, a support structure that actively contributes to the emergence of certain 
decisive cancer-related capabilities [8]. 
When a tumor is forming, the local conditions are altered, which means that the 
developing tumor will be enclosed in an environment completely different from the one that 
is associated with normal cells. This is called the tumor microenvironment (TME) and includes 
surrounding non-tumor cells like endothelial cells, fibroblasts and immune cells that are 
embedded into the tumor tissue by extracellular matrix proteins. Soluble factors, signaling 
molecules and mechanical cues that promote malignant transformation and support the 
tumor’s growth and invasion are also part of the TME [16, 17].  
The microenvironment is characterized by low oxygen levels or hypoxia, low glucose 
concentrations and overexpression and hypersecretion of a number of hydrolytic enzymes in 
different stages of tumor progression that form the liquid milieu of the TME. A micro-acidic 
environment is common in most solid tumors, with an extracellular pH (pHe) ranging from 5.3 
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to 7.2, as a consequence of the aforementioned events. The acidity may favour the activity 
of proteases with a slightly acidic optimal pH such as cysteine and aspartic cathepsins, as 
well as the redistribution of lysosomes in the cell surface for the release on their proteases 
[16, 18]. 
The interactions between all of the TME’s components are essential for the correct 
regulation of the self-renewal and differentiation processes fulfilled by the tumor’s stem cell 
niche to promote the tumor cells’ indefinite proliferation [17]. Elements of its 
microenvironment can actually be instructive to tumor cells, making them more or less 
tumorigenic and even  maintaining or inducing a cancer stem-like state through the secretion 
of certain molecules (the secretion of hepatocyte growth factor by myofibroblasts in the 
microenvironment of colorectal cancer is an example) [17, 19]. Although its general 
constitution remains the same, a specific tumor developed in a certain tissue will have 
determined factors, signals and molecules that might not be present in another tumor type 
since their differences implicate other kinds of stimuli. Research on the specific 
microenvironments of, for instance, breast [20, 21] and lung [22] cancer, Hodgkin lymphoma 
[23], B-cell chronic lymphocytic leukemia [21] and neuroblastoma [24] produced results that 
prove as much. 
The genesis and progression of cancer is a process that occurs through a sequence of 
steps, which is confirmed by the fact that the transformation of normal cells into malignant 
ones requires progressive genetic alteration [25]. Cancer genesis can be divided into three 
phases: initiation, promotion and progression [5]. The first step is initiation and involves a 
change in the normal cells’ phenotype due to irreversible mutations in its DNA. These are 
induced by initiators, which, if not already reactive with DNA, are altered by drug-
metabolizing enzymes, being then able to cause mutations in the DNA [26, 27]. Promotion is 
the process through which the initiated cells progress into a visible tumor [28]. This process is 
undoubtedly related to epigenetic factors. The promoters do not directly interact with the 
DNA. Instead many bind to cell membrane receptors and affect internal pathways – specific 
promoters. Nonspecific promoters, on the other hand, alter gene expression without the 
presence of a known receptor. Both of them generally further alter the cell so it proliferates 
and divides, which results in their ability to grow unregulated. Promoters do not act on cells 
that have not undergone initiation and are usually specific to a certain type of tissue [3, 29, 
30]. At this point the lesion is benign. To acquire malignancy, the cells must undergo 
heritable mutations that greatly influence their histopathological characteristics of cellular 
morphology, invasiveness, growth, and differentiation.  This process is called progression. 
The three stages are represented in figure 1. 
 
 
 
 
 
Figure 1 Schematic representation of the development of a tumoral mass of cells. Here are represented 
the three main steps of cancer ethiology – initiation, promotion and progression [31]. 
 
These mutations can be caused by variability inducing phenomena, namely point 
mutations, genetic amplification or chromosomal translocation. Usually, the occurrence of 
malignant phenotype in a cell requires not only one but several alterations of its genome that 
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are accumulated over time. The cell’s DNA can suffer spontaneous mutations or they can be 
inherited from parents. An example for the last case is related to breast cancer – women that 
inherit a defective copy of the BRCA1 and BRCA2 genes are on greater danger of developing 
pathology [32]. Many external factors, usually combined, are also involved in the generation 
of cancer associated mutations. An unhealthy diet, excess body weight and little physical 
activity are all factors that can increase the risk of cancer. The abuse of substances such as 
alcohol and tobacco also increases the risk of cancer [15]. Moreover, Ultraviolet (UV) 
radiation, which comes from the sun and man-made sources like tanning beds, is able to 
affect cells of the epidermis, the most superficial layer of the skin, originating basal and 
squamous cell skin cancer or the less common but more serious melanoma, most frequently 
on more exposed areas such as the face, neck and arms [25]. Other high energy radiation 
types, like the X rays and gamma radiation used for medical purposes and nuclear power 
plants, are also associated with tumor generation, as well as some chemicals and infectious 
agents [3, 15, 25]. Carcinogen types are as listed below: 
-Lifestyle factors (nutrition, tobacco use, physical activity, etc.); 
-Naturally occurring exposures (ultraviolet light, radon gas, infectious agents, etc.); 
-Medical treatments (chemotherapy, radiation, immune system-suppressing drugs, etc.); 
-Workplace exposures; 
-Household exposures (food irradiation, consumer products containing radiation); 
-Pollution [5]. 
Any healthy nucleated cell possesses mechanisms to repair its DNA and maintain the 
stability of its genetic content. These mechanisms regulate cellular processes that increase 
the probability of mutations, such as DNA replication, chromosome segregation and others. 
When the repair mechanisms are surpassed, the DNA cannot be repaired. As a consequence, 
the control of the production and release of growth factors that happens regularly in healthy 
cells ceases to be done efficiently [33]. The subsequent mutations generate more and more 
variability in the genome of the daughter cells and the ones with a higher survival rate are 
selected leading to a higher cellular heterogeneity and finally to a state of chronical 
proliferation associated with tumor cells [5]. 
The transformation of healthy cells into cancer cells results of mutations mainly in genes 
of the following types:  
- Proto-oncogenes: genes that usually regulate cell division, apoptosis and 
differentiation; through the action of carcinogens they can become oncogenes, which 
promote malignant alterations; 
- Tumor suppressant genes: genes that suppress alterations that could lead to cancer; 
as a result, their inactivation is involved in carcinogenesis [27]. 
The tumor cells achieve immortality by controlling their own proliferative signals. This 
happens through a few alternative mechanisms. Cells can produce their own growth factors, 
to which they respond by expressing specific receptors for them – autocrine proliferative 
stimulation. Alternatively, they can stimulate normal cells in the supporting tumor-associated 
stroma to supply the cancer cells with the required growth factors [25, 33]. They can also 
increase the expression of surface receptors or change their conformation in order to make 
them hyperresponsive to growth factor ligand concentrations that would be limiting 
otherwise. Several studies using DNA sequencing analysis of cancer cell genomes have 
revealed somatic mutations that implicate the constitutive activation of signaling circuits 
usually triggered by activated growth factor receptors [34]. 
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The growth of functional cancer cells also requires cellular senescence to be stopped or 
delayed and that the cells in the interior of the tumor mass are being supplied with nutrients. 
The first need is satisfied by the fact that the enzyme telomerase, almost inexistent in 
normal cells, is present and active in cancer cells, which supports the knowledge that, during 
the transformation process to malignance, the cells suffer dedifferentiation and loss of 
function [5, 33]. Nutrients are carried to the interior of the tumor by blood vessels formed for 
that exact purpose through angiogenesis motivated by the vascular endothelial growth factor 
A (VEGF-A), for instance, and its expression can be stimulated by oncogenes [15, 27, 35]. 
Another characteristic of cancer is the acquisition by the cells of the ability to invade 
tissues besides the one they were originally formed in. This is a process named metastization 
and involves the propagation of cancer cells to different tissues of the body, starting by the 
insertion of cancer cells in the lymphatic and blood vessels near the original tumor. These 
cells then circulate in these systems and end up diffusing to the parenchyma of distant 
tissues where they constitute cancer cell nodes (micro-metastasis) that then develop into 
macroscopic tumors. 
It can therefore be concluded that cancer cells possess a setting of capabilities that 
strictly differentiate them from normal cells [8], such as: 
- Enabling replicative immortality; 
- Inducing angiogenesis; 
- Resisting cell death; 
- Sustaining proliferative signaling; 
- Evading growth suppressors; 
- Activating invasion and metastasis. 
 
1.1.2. Conventional Therapies 
Throughout the years the knowledge on the pathophysiology of cancer has been enlarged 
through constant research. The better understanding of its causes and types favored the 
development of therapies that succeed in the treatment or restriction of cancer. The concept 
of targeted therapy is still under development but there are nowadays techniques that 
produce good results in treating cancer. Although hyperthermia, immunotherapy and stem 
cell transplant are also being used, the most used and also most effective techniques until 
now will be described below [25, 36]. 
Surgery is a type of treatment that can be performed for diagnosis, to evaluate the stage 
of the disease and for reduction or removal of the tumor mass. Surgeries performed for 
diagnosis are called biopsies and involve the removal of a small portion of tissue from various 
regions of the affected organ to be analyzed. Surgeries that aim the treatment of the 
condition consist, as said, in tumor removal or are performed to mitigate the effects of the 
disease. Surgeries can be very invasive (open body surgery, laparoscopy) or less invasive 
(laser surgery, endoscopy) [25]. The choice depends on factors such as the stage of the 
disease, the patient’s age and other health problems they might suffer from [37, 38]. If 
surgical remotion of the entire tumor is possible, this therapy can rapidly eliminate the 
pathology practically by itself. However, it poses some disadvantages since it is useless in the 
case of liquid or circulating tumors and very ineffective in metastized tumors, being mostly 
used in association with one of the next therapies. It is also an invasive procedure that makes 
patients vulnerable to a number of other complications such as infection [3, 39]. 
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Radiotherapy on the other hand consists of the application of radiation, usually X or 
Gamma, to the treatment of cancer. Radiation damages the DNA of the dividing cancer cells, 
which become unviable and undergo cell death. Therefore, radiotherapy allows the reduction 
of tumor size by leading to the death of the cells that form it. However, this is more a 
contemption procedure than it is a cure, being usually utilized coupled with other treatment 
options, mainly chemotherapy. Another problem with this technique is that it doesn’t affect 
only cancer cells. It acts on cells undergoing division in every tissue, damaging healthy cells 
as well and causing secondary effects in short (skin, intestines and other rapid-growing 
tissues) and long term (bone and nervous tissue). Consequently, the therapy needs to be used 
while assuring the balance of the organism upon the damage caused, which poses some 
difficulties in its use [2, 3, 40, 41]. 
Chemotherapy is the most used type of treatment for cancer since it seems to very 
effective [32]. It involves the use of natural or synthetic chemical compounds in order to 
destroy infecting agents or cancer cells. It can be performed on its own or coupled with one 
or more of the aforementioned alternative therapy methods, depending on the type and 
stage of the pathology [3]. 
Chemotherapy can be administered in different clinical settings, such as: primary 
induction chemotherapy, for the treatment of advanced, metastatic cancer, for which the 
possibility of cure is remote and the goal is to increase the survival time and the quality of 
the patient’s life; neoadjuvant chemotherapy, used for localized tumors (anal, bladder, 
breast, esophageal, laryngeal and non-small cell lung cancers) for which alternative methods 
exist but are less efficient than desirable, leads to good results when coupled with 
radiotherapy; and adjuvant chemotherapy, used after another treatment option to prevent 
recurrence, is effective in prolonging the survival of the patients after removal or remission 
of the tumors [7]. 
The therapies that involve drugs are constantly evolving once, much like microorganisms, 
cancer cells have the ability to develop genetic alterations that grant them drug resistance. 
This was also the motive that led to the development of combined chemotherapy, which 
consists of the introduction of more than one type of drug in the organism, which allows the 
treatment of the disease on different levels and through distinct mechanisms leading to a 
higher efficacy and lower susceptibility to possible resistance by the cells  [3, 42]. 
Nowadays it is known that a determined dose of drugs used in chemotherapy could be 
enough to eradicate a certain amount of malignant cells. Thus, correlating the dose with the 
size of the tumor, it would be theoretically possible to eliminate it quickly and definitively. 
However, the fact the cancer cells derive from cells from the same individual makes it so 
that they share a few characteristics with cells in various tissues of the body. Therefore, the 
effects of the drugs occur also in healthy cells and so a drastic session is not an option. 
Instead, sequential but spaced chemotherapy sessions have to be scheduled so the patient 
doesn’t sustain lethal injuries from the treatment [3, 42]. 
Most currently used drugs on chemotherapy act on a particular characteristic of cancer 
cells – cell division. Consequently, cells in the G0 stage of the cell cycle are unaffected. On 
the other hand, cells in the S stage suffer damage to their DNA that leads to apoptosis. Just 
like radiation would, these drugs act both on malignant and rapidly growing healthy cells, 
causing side effects such as impaired wound healing, lower leukocyte production 
(compromising the immune system), hair loss, infertility and teratogenicity. 
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Table 1 Some of the most used chemotherapeutic agents from each type and their 
mechanisms of action and main side effects [7]. 
Type Drug Mechanism of Action Side Effects 
Alkylating agent 
Cyclophosphamide 
Alkylates the DNA at the N7 position 
of guanine; inhibits DNA synthesis. 
Nausea, vomiting, Bone marrow 
suppression, leukopenia, 
thrombocytopenia, alopecia, 
hemorrhagic cystitis 
Cisplatin 
Nausea, vomiting, Bone marrow 
suppression, renal dysfunction, 
acoustic nerve dysfunction. 
Procarbazine 
Nausea, vomiting, 
myelosuppression, hemolytic 
anemia, pulmonary effects. 
 
Dacarbazine 
Nausea, vomiting, 
myelosuppression 
Mustines 
Alkylates the DNA through cross-
linking. 
Nausea, vomiting, 
myelosuppression. 
Antimetabolite 
 
Methotrexate 
Binds to the catalytic side of 
dihydrofolate reductase, inhibiting 
the folic acid pathway. 
Bone marrow suppression; 
dermatological damage and to the 
gastrointestinal mucosa. 
 
Mercaptopurine 
Activation by hypoxanthine-guanine 
phosphoribosyl transferase (HGPRT) 
to form 6-thioinosinic acid which 
inhibits enzymes involved in purine 
metabolism. 
Hyperuricemia, acute gout, 
nephrotoxicity. 
Thioguanine 
Substitution of guanine bases leading 
to inhibition of DNA and RNA 
synthesis. 
5-Fluorouracil 
One derivative inhibits thymidine 
synthesis, the other incorporates 
RNA, in general, DNA and RNA 
synthesis is inhibited. 
Myelosuppression, mucositis. 
Cytarabine 
Active form competes and inhibits 
DNA polymerase, inhibiting DNA 
synthesis but not RNA. 
Nausea, alopecia, stomatitis, 
severe myelosuppression. 
Gemcitabine 
Competes with cytidine and replaces 
it in DNA formation, inhibiting 
replication. 
Nausea, fever, headache, fatigue, 
vomiting, poor appetite, allergic 
reaction, difficulty sleepy, 
shortness of breath. 
Plant Alkaloid 
Vinblastine 
Microtubule depolarization, which 
interferes with chromosome 
segregation causing mitotic arrest at 
metaphase. 
Nausea, vomiting, alopecia, bone 
marrow suppression. 
Vincristine 
Bone marrow suppression, 
neurotoxic reactions. 
Etoposide 
Inhibits topoisomerase II, which leads 
to DNA damage and cell cycle arrest 
at late S or G2 phase. 
Nausea, vomiting, alopecia, 
hematopoietic and lymphoid 
toxicity. 
Paclitaxel 
Enhanced microtubule 
polymerization, forming bundles that 
lead to mitotic arrest. 
Vomiting, diarrhea, alopecia, 
neutropenia, thrombocytopenia, 
peripheral neuropathy. 
Antibiotics 
Anthracyclines 
(doxorubicin and 
daunorubicin, 
epirubicin) 
Intercalate the DNA and affect 
topoisomerase II inhibiting DNA and 
RNA synthesis, alter membrane 
fluidity and ion transport, and 
produce and oxygen radical species. 
Permanent heart damage, nausea, 
vomiting, myelosupression, 
alopecia. 
Bleomycin 
Produces single and double stranded 
breaks due to free radical formation, 
arresting the cell cyle in phase G2. 
Anaphylactoid reaction, fever, 
anorexia, hyperkeratosis, 
blistering. 
Hormonal Agent Tamoxifen  
Partially competes with estrogen, 
binding to estrogen receptors and 
suppresses serum levels of insulin-
like growth factor-1; and up-
regulates local TGF-beta production. 
Hot flashes, nausea, fluid retention 
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1.1.3. Anticancer Drugs 
The most used types of anticancer drugs are called cytotoxic agents and can be divided 
in various categories. 
Alkylating agents and derivatives establish covalent bonds with the DNA and prevent its 
replication. Antimetabolites block or subvert metabolic mechanisms of DNA synthesis. In 
this category there are purine anthagonists, like mercaptopurine and gemcitabine, and 
pirimidine anthagonists, such as 5-fluorouracil and cytarabine, which are drugs that 
compete with regular bases and are added as such to forming chains or influence enzymes 
associated with their metabolism or synthesis. Other pathways can also be affected by this 
type of drug, being a good example the folate metabolism. The cells need folate naturally 
to perform regular and essential functions like synthesising, repairing and methylating DNA. 
Fast growing cells like cancer cells need an even higher amount of folate. In the case of 
folate anthagonists like methotrexate, the drug binds to the enzyme responsible for 
converting folate to its active form, inhibiting this process and therefore depriving the cell 
of folate. Cytotoxic antibiotics are able to interfere with several mechanisms (depending on 
the antibiotic) in DNA replication and protein synthesis. Plant derivatives, such as alkaloids, 
taxanes and campothecins, impair the correct functioning of microtubules, interrupting the 
mitosis. Hormones are also used, especially steroids, as well as compounds that suppress or 
antagonize hormone secretion. A number of compounds that include the recent tumor-
related targets cannot be included in any of the previous categories [3, 43]. Table 1 shows 
some of the most applied chemotherapeutic drugs along with their type, mechanism of 
action and side effects. 
Due to the development of resistance by the cancer cells to the anticancer drugs and 
the lack of definitive and 100% successful cure, new drugs are currently being researched 
for their possible advantageous effects comparing to the ones already in use. An interesting 
new category are the alkyl lysophospholipids, ALP. Edelfosine appears to be the most potent 
anticancer ALP. It is particularly interesting since, unlike most chemotherapeutic drugs, it 
does not attack DNA. Instead, edelfosine accumulates in the lipid rafts of the membranes of 
tumor cells, apparently inducing apoptosis through a redistribution of lipid raft protein 
composition [44, 45]. 1-aryl-3-(2-chloroethyl) ureas or CEUs also present strong anticancer 
effects that led their intensive use in several studies. CEUs are hybrids of two also potent 
anticancer agents, aromatic nitrogen mustards and aliphatic nitrosoureas. They have shown 
to be very cytotoxic, devoid of mutagenicity and show no signs of systemic toxicity in 
animal models with tumors. They are weak alkylating agents that are unable to alkylate 
either cellular DNA or gluthatione, so the low alkylating potency is only partially responsible 
Miscellaneous 
Hydroxyurea 
Blocks an enzyme which converts the 
cytosine nucleotide into the deoxy 
derivative and the incorporation of 
the thymidine nucleotide into the 
DNA strand, inhibiting DNA synthesis. 
Drowsiness, nausea, vomiting, 
diarrhea, alopecia, anorexia, 
mucositis, stomatitis, bone marrow 
suppression. 
L-asparaginase 
Depletes serum asparagines that the 
tumor cells need but cannot 
produce, leading to cell death. 
Allergy, anaphylaxis, pancreatitis. 
Oxaliplatin 
Forms both inter- and intra-strand 
cross links in DNA which prevent DNA 
replication and transcription. 
Nausea, vomiting, diarrhea, 
neurotoxicity, neutropenia, 
ototoxicity. 
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for their cytotoxicity. These are amphiphilic drugs that therefore can interact with the 
lipids in the membrane, so alteration of the membrane’s fluidity is thought to be the major 
cause of cytotoxicity [46]. The general structure of CEUs can be seen in figure 2. 
 
Figure 2 General structures of CEU derivatives substituted at positions four (top) and two (bottom). “R” 
representes the substituent groups (also called radical groups). The only difference between distinct 
CEUs is this R (radical) substituent [46]. 
Although chemotherapy can be performed using only one agent, introducing a 
combination of different drugs into the organism is much more common. That is because the 
combination of different types of drugs can target different pathways on the cells, making 
the therapy more efficient, and also provide a way to surpass drug resistance by cancer cells 
[32]. In Table 2 are shown a few common established combination regimens for 8 distinct 
types of cancer.  
 
Table 2 An assortment of very common and established combination chemotherapy regimens. 
Adapted from Corrie et al. 2011 [47]. 
Cancer Combination of Drugs 
Breast -Cyclophosphamide, methotrexate, 5-fluorouracil; 
-Doxorubicin, cyclophosphamide. 
Hodgkin’s Disease -Mustine (nitrogen mustard), vincristine, procarbazine, 
prednisolone; 
-Doxorubicin, bleomycin, vinblastine, dacarbazine. 
Non-Hodgkin’s Lymphoma -Cyclophosphamide, doxorubicin, vincristine, prednisolone. 
Germ Cell -Bleomycin, etoposide, cisplatin. 
Stomach -Epirubicin, cisplatin, 5-fluorouracil. 
Bladder -Methotrexate, vincristine, doxorubicin, cisplatin. 
Lung -Cyclophosphamide, doxorubicin, vincristine (etoposide). 
Colorectal -5-fluorouracil, folinic acid, oxaliplatin. 
It can be gathered from Table 2 that each drug combination includes drugs with different 
mechanisms of action, which may be associated with the importance of eliminating as much 
cancer cells as possible as well as overcoming possible drug resistance as mentioned before. 
Also, the differences in combinations support the idea that different types of cancer involve 
different mechanisms and molecules [48]. 
Targeted cancer therapies, on the other hand, are more specific as they try to eliminate 
the pathology by acting on specific molecular targets associated with cancer, blocking the 
growth and spread of cancer cells. Through these therapies, side effects can be minimized 
since the specificity towards cancer-related targets decrease or halt the action of the drugs 
on normal cells [49]. Although targeted cancer therapies are relatively new, very subjective 
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and still under development, the kind of strategy they present might be key in the future of 
cancer treatment.   
1.2 - Biological Membranes 
Cellular membranes are some of the most important components of cells. Besides their 
essential function in the compartmentalization of the cells, whether it is separating the cell 
contents from the environment in the case of the plasmatic membrane or creating a boundary 
between the inside of the cell’s organelles and its cytoplasm, biological membranes are 
involved in a number of other processes that are crucial for the development of cells and 
organisms in general [50]. These functions are mainly regulated and made possible by the 
very diverse constitution of the membranes. 
The universal basis for cell membranes’ structure has been since 1925 established to be 
the lipid bilayer [3]. The lipid bilayer is formed by a variety of amphiphilic molecules 
unevenly distributed and held together by hydrophobic interactions between their acyl 
chains. In 1972, Singer and Nicholson proposed that the membrane was structured as a fluid 
mosaic, a highly dynamic, heterogeneous and asymmetric structure composed of lipids and 
proteins that moved and changed conformation freely within the membrane’s plane. The 
fluid mosaic model is still the basis of knowledge in regards to the membrane bilayer, but 
currently there is much more information regarding its constitution and the interaction 
between its constituents at a molecular level [50, 51].  
Cell membranes are characterized by an asymmetric distribution of lipids along the 
bilayer. These lipids are mostly phosphatidylcholine (PC), phosphatidylethanolamine (PE) and 
phosphatidylserine (PS), as well as sphingomyelin (SM), phosphatidylinositol (PI) and 
cholesterol in smaller proportions, represented in figure 3 [50]. Cholesterol is a very 
important constituent of the membrane because it is the main molecule responsible for the 
maintenance of membrane’s fluidity. This molecule has a hydroxyl group that interacts with 
the hydrophilic head groups of the other lipids in the membrane, while its bulky steroid 
groups interact with their hydrophobic acyl chains, as can be seen in figure 4. 
These interactions modulate the packing of the lipids within the membrane, influencing 
its fluidity [50]. Membrane fluidity is one of the most important psychochemical 
characteristics of biological membranes since it affects several cell functions such as cell 
growth, carrier-mediated transport and enzyme and receptor-related signalling pathways like 
apoptosis. Proteins also integrate the membranes. Integral proteins span the entire 
membrane while peripheral proteins usually adhere to the surface of the membrane via 
protein-protein interactions. Proteins can contribute as molecule or ion transporters or 
anchors and are involved in a variety of biological processes [52]. 
This asymmetric distribution of lipids on the membrane is associated with the 
aforementioned lipid rafts and is maintained purposely by the cell at the expense of energy, 
which confirms its importance to the cell’s functioning [53]. An important aspect of this 
asymmetry is that in normal cells anionic aminophospholipids (mainly PS) are maintained on 
the inner leaflet of the membrane [53-55]. This is important because PS exposure at the 
surface of cells has been correlated with the maintenance of the membrane structure as well 
as some of its functions, allowing the binding of membranes proteins, being a cofactor for 
protein kinase C or PKC and the Na+/K+ ATPase and the promotion of a blood clotting 
cascade, and so it is essential that, at a normal state [54, 56], PS is not exposed. Contrarily, 
 Assessment of Anticancer Drugs’ Effects on Membrane Biophysical Properties using Model Membranes 
 
11 
 
it has been shown that PS is exposed in high amounts on the outer leaflet of tumoral cell 
membranes [54], and that has actually became a major hallmark that could in the future be 
an excellent target for the delivery of drugs. The same seems to happen with PE, although its 
involvement in the membrane behaviour seems to be smaller [56]. 
So it is clear that the constitution and structure of the cell membrane differs greatly from 
normal to tumoral cells. Interestingly, slight changes can be seen even between the structure 
and composition of the membranes of different types of cancer cells. Studies on hepatoma 
cells showed that their membranes contained four times more SM than normal ones, as well 
as an increase in choline plasmalogen and unsaturated fatty acids, which might indicate 
higher membrane fluidity [57]. In human colorectal cancer cells, increased levels of all 
phospholipids were found, including PI, PS, PE and PC, which is associated with enhanced cell 
membrane synthesis [53, 58].  The membranes of lymphocites from patients with Chronic 
Lymphocitic Leukemia or CLL present an increase in general phospholipid concentration as 
well as cholesterol, SM and glucosylceramide and lactosylceramide while a decrease of the PC 
levels was observed when comparing the membrane fraction with the general homogenate 
[59]. Hairy cells from hairy cell leukemia (HCL) have membranes with higher content in 
cholesterol and lower fluidity than CLL lymphocites. However, the cholesterol content is 
similar to that found in normal monocytes [60]. It becomes therefore evident that cell type 
influences plasma membrane constitution, which could be a stepping stone towards 
developing new therapies or drug delivery systems specifically targeting certain tissues or 
tumoral cell types. 
 
 
 
 
 
Figure 3 Representation of the structures of some of the main lipids found in animal plasma membranes: 
phosphatidylethanolamine (A), phosphatidylserine (B), phosphatidylcholine (C) and sphingomyelin (D), 
which are phospholipids. Glycolipids appear in a much smaller amount, but the most common are 
galactocerebroside (E), GM1 ganglioside (F) and sialic acid or NANA (G). Adapted from Alberts et al. 2002 
[2]. 
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The membrane’s heterogeneity leads to the formation of microdomains in its structure 
[50]. Some of these microdomains are called lipid rafts and are made of cholesterol and 
sphingolipids [glycosphingolipids and shpingomyelin (SM)]. The lipid rafts actively participate 
in metabolic and signal transduction processes, and some of these processes are even 
involved in the promotion of cell death (like the Fas receptor death pathway)[51]. 
 
Figure 4 The structure of cholesterol is represented by formula (A) and by schematic drawing (B). (C) 
represents the cholesterol’s interaction with lipids in the bilayer. Adapted from Alberts et al. 2002 [61]. 
 
1.2.1. Importance for drug-membrane interaction studies 
Plasma membrane is a complex and intricate structure involved in a variety of life-
defining events for the cell. Besides the already mentioned importance of membrane 
proteins, changes in lipid levels have been described in a number of pathologies, namely 
cardiovascular diseases and cancer [3, 62-64]. Due to the highly prolific character of cancer 
cells, they have constitutive activation of fatty acid biosynthesis, which has been 
demonstrated to lead to altered phospholipid and fatty acid profiles in breast cancer cells 
and surrounding tissue [65]. Gangliosides were shown to be aberrantly distributed in a 
number of tumors and an accumulation of esterified cholesterol was associated with cell 
cycle progression and tumor growth. Sphingomyelin levels were reduced in a number of 
cancers as well [66]. 
It appears that the plasma membrane is also a very important participant in 
chemotherapy-induced cell death since the targets for the main chemotherapeutic drugs are 
thought to be intracellular, as well, as in the effect of a variety of other decisive drugs 
(antibiotics, antifungal drugs, etc.), but very little is understood about the actual processes 
and the way that the membrane is involved in them [51, 65, 67]. Indeed, the ultimate effect 
of the drug might be a consequence of the actual interaction of the drug with the plasma 
membrane or be related to the interaction with an intracellular target. Certain drugs can 
interact with the membrane’s proteins, which can act as receptors, signal transducers, 
transporters or enzymes. Others act on the actual lipid bilayer, altering its biophysical 
properties such as permeability (so the drug can enter the cell or to disrupt the membrane 
leading to cell death), phase behavior and conformation. Either way, an interaction with or 
penetration of the cell membrane is a crucial step in the drug’s activity, especially in the 
case of anticancer drugs [65, 68].  Other membranes (such as nuclear envelope, Golgi and 
reticulum membranes) might also be involved in the mentioned processes. Several studies 
have actually proved that there is a correlation between the cytotoxicity of certain antitumor 
agents and, for instance, membrane fluidity, as well as other parameters [46]. Therefore, the 
study of the interactions between these drugs and membranes is of vital importance since it 
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could shed light on the drugs’ activity and therefore on its pharmacology, pharmacokinetics, 
efficacy and toxicity [69]. Furthermore, the knowledge that can be obtained from the study 
of drugs-membrane interactions could allow the improvement of drugs mechanism of action 
and the development of new drug  delivery systems [68, 70]. 
 
1.2.2. Types of Model Membranes 
The complex constitution of the membrane as well as its behavior is very beneficial for 
the cell in a way that they modulate very important processes as previously mentioned. 
However, besides the difference in phospholipidic constitution and the existence of 
microdomains, the molecular shape (polymorphism) of lipids, the different degrees of affinity 
between them, the charge, the differential electrostatic interactions and other factors also 
affect the membranes’ behavior and structure. This intricacy and complexity creates great 
difficulties in the study of the referred processes, and, most importantly in the case of this 
review, in the study of anticancer drug-membrane interactions [50, 68, 71]. The solution lies 
in the use of artificial model membranes. These model membranes can be manufactured with 
the desired constitution and maintained in controlled conditions, and can be used to mimic 
simple or complex cases by just varying its lipid composition. Lacking the remaining 
constituents of an actual cell, these models are not subjected to several factors that could 
arise from differences in intracellular molecules, processes or conditions, which could 
interfere with the results obtained. 
 
 
Figure 5 Schematic representation of a biological membrane and its constituents [3]. 
A wide variety of mimetic model systems exists and is currently used for the study of 
drug-membrane interactions. In this particular case, the review will center our attention on 
those used for studies regarding the effect of anticancer drugs on model membranes. The 
review of these studies, discussed in the section below, resulted in the conclusion that lipid 
monolayers, lipid bilayers and liposomes are the most used model membrane systems used to 
assess the effects of anticancer drugs, although micelles also play a smaller but important 
role in these. 
A. Lipid Monolayers 
Lipid monolayers may be the simplest form of lipid model. They can also be called 
Langmuir monolayers and are formed at the air-water interface in a Langmuir through by 
accumulation of the lipids with a cylindrical shape in the lipid solution at the surface with the 
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hydrophilic head in contact with the water and the hydrophobic tails turned upwards [68]. 
Since these type of lipids have a shape that does not allow the formation of curvature, the 
structure is maintained as a plane layer [66]. 
B. Lipid Bilayers 
Lipid bilayers are basically two monolayers placed together. Their structure is generally 
the one that can be found in plasma membranes: a bilayer of lipids in which the polar heads 
are turned to the outside, where they can interact with water and aqueous solutions, and the 
hydrophobic lipid tails are placed on the core of the bilayer [72]. 
Both monolayers and bilayers can also be supported lipid monolayers or bilayers. In this 
case, instead of being at an air-water interface, these structures are adsorbed to a solid 
surface like mica or gold [73]. 
C. Micelles  
Micelles are vesicles delimitated by a lipid monolayer of conical-shaped lipids. This shape 
makes the monolayer curve until a closed vesicle is formed. Depending on the shape of the 
lipid, the micelle can be a regular one, with the polar heads turned outwards and the 
hydrophobic tails turned to the inside, or an inverted micelle in which the opposite occurs 
[66, 69]. 
D. Liposomes 
Liposomes are a more complex but also a much more versatile model to study drug-
membrane interactions. These structures are basically vesicles with a lipid bilayer as a 
surrounding membrane. These vesicles can differ both in size and number of bilayers. 
Liposomes with multiple concentric bilayers separated by liquid are designated multilamellar 
lipid vesicles  (MLVs); while unilamellar vesicles have only one lipid bilayer and, depending on 
their size, they are classified as small unilamellar vesicles (SUVs), large unilamellar vesicles 
(LUVs) or giant unilamellar vesicles (GUVs) [74]. 
1.3 - Anticancer Drug-Membrane Interaction Studies 
1.3.1. Techniques applied in anticancer drug-membrane interaction 
studies 
It has so far been described the importance of lipid model membranes in the study of 
drug-membrane interactions, but its importance only exists if there are techniques to study 
those interactions. Along with the development of novel model membranes, a wide variety of 
techniques have been develop to better understand these interactions and in order to assess 
not only the partition or location of the drug in the membrane, but also its conformation and 
orientation upon interaction with it, as well as the changes in lipid phase, structure, stability 
and even at a molecular or elementary level  upon drug presence [75, 76]. Table 3 correlates 
the most used techniques in this field with the model membranes that are frequently used 
with and its respective goal. 
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Table 3 Experimental techniques applied to the study of anticancer drug-membrane interaction studies using different membrane mimetic models. 
Technique 
Type of model 
membrane 
Biophysical parameter studied References 
DSC 
MLVs 
Effect of squalene-gemcitabine, tamoxifen, paclitaxel, cisplatin and methotrexate on the lipid phase transition 
temperatures [77-82] 
SUVs 
Effect of paclitaxel, etoposide and cytarabide on the lipid phase transition temperatures 
[80, 83] 
SAXS 
MLVs 
Effect of squalene-gemcitabine on structural parameters and phase behavior of bilayers 
[77] 
Lipid Bilayers 
Effect of  squalene-gemcitabine on structural parameters above and below the transition 
[84] 
LUVs 
Effect of doxorubicin on the packing details of the membranes 
[85] 
WAXS 
MLVs 
Effect of paclitaxel on structural parameters and phase behavior of bilayers 
[77] 
Lipid Bilayers 
Effect of squalene-gemcitabine on structural parameters above and below the transition 
[84] 
Monolayer 
Techniques 
Lipid 
Monolayers 
Assessment of edelfosine, doxorubicin and paclitaxel’s capacity of penetrating into the monolayer 
[44, 45, 86-90] 
Fluorescence 
measurements 
Lipid 
Monolayers 
Effect of edelfosine on the lipid structure; assessment of the formation of edelfosine-lipid micelles 
[44] 
LUVs 
Effect of doxorubicin, edelfosine and 2-hydroxyoleic acid (2 OHOA) on the membrane structure and permeability; 
partition of the drug 
SUVs 
Assessment of doxorubicin’s capacity of penetrating into the bilayer 
[87] 
Micelles 
Assessment of doxorubicin’s capacity of penetrating into the monolayer 
[87] 
Turbidity LUVs 
Assessment of bilayer solubilization as an effect of edelfosine 
[44] 
FT-IR 
SUVs 
Determination of changes in membrane structure and dynamics upon interaction with etoposide and cytarabide 
[83] 
MLVs 
Effects of acyl chain length on structural parameters such as lipid order and the strength of hydrogen bonding 
under the effect of tamoxifen [78, 79] 
MLVs 
Determination of changes in membrane structure and dynamics upon interaction with CEUs 
[46, 91] 
Lipid Bilayers 
Effects of CEUs on the gel-to-liquid–crystalline phase transition temperature of the acyl chains of the lipid; study 
of CEU incorporation into the bilayer [46] 
Phase Contrast GUVs 
Effects of ODPC on membrane structure 
[92] 
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Microscopy 
BAM 
Lipid 
Monolayers 
Effects of edelfosine on the morphology of the monolayer 
[45] 
NMR 
MLVs 
Study of the influence of CEUs on the membrane phase behavior and conformation 
[91] 
Lipid Bilayers 
Study of the influence of cisplatin on the phase behavior and conformation of the bilayer 
[93] 
Liposomes 
Study of the influence of cisplatin on the phase behavior and conformation of the bilayer 
[94] 
EPR MLVs and SUVs 
Determination of changes in membrane structure and dynamics as an effect of paclitaxel presence 
[80] 
Circular 
Dichroidism 
LUVs 
Assessment of doxorubicin’s partitioning 
[85, 95] 
DLS MLVs 
Determination of the effect of doxorubicin on phase transition temperature 
[88] 
Cyclic Voltametry 
Supported 
Lipid 
Monolayers 
Assessment of doxorubicin’s partitioning conditions 
[89] 
SERRS 
Supported 
Lipid 
Monolayers 
Assessment of doxorubicin’s interactions with the monolayer (penetration or binding) 
[89] 
QCM and SPR 
Supported 
Lipid 
Monolayers 
Quantification of the doxorubicin that is able to interact with the monolayer 
[89] 
2D TLC MLVs 
Study of the complexation of cisplatin with the membrane in the presence of a competitor (glutathione) 
[96] 
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From the information presented in Table 3 it appears that the most used model 
membranes are lipid monolayers and bilayers (MLVs and LUVs). Lipid monolayers are the 
simplest model membrane, with a typically smooth structure that is easy to create and 
monitorize. The main conditions to have in mind, such as pH, ion content, temperature, and 
surface pressure are easily controlled [97]. Bilayers, although a little more complex in 
structure, share some of these characteristics, which also makes them a preferred model 
[97]. In the case of liposomes, some techniques benefit from the use of a higher amount of 
sample, and so MLVs are a good choice [76]. However, unilamellar vesicles also have its 
relevance, particularly LUVs due to the fact that their membrane curvature is similar to that 
of cells [75, 76]. 
In the case of liposomes and lipid bilayers that can be generically called models with 
bilayered membranes, differential scanning calorimetry (DSC) is one of the most often used 
techniques, along with SAXS and WAXS, NMR, FT-IR and Circular Dichroidism (CD). 
The physicochemical properties of phospholipids lead them to form bilayers 
spontaneously, and the bilayer’s physical organization highly depends on temperature, type 
of phospholipid and water-lipid ratio. For instance, at higher temperatures, a bilayer can be 
organized in the liquid crystalline phase (Lα) and as the temperature decreases it changes to 
the gel phase (Lβ) with limited movement of the hydrocarbon chains. This is important 
because the lipid phase of the majority of the phospholipids in a membrane is directly related 
to the degree of disorder of its lipids and therefore the membrane’s fluidity. This can be 
better understood in figure 6. DSC is a thermodynamics technique that is able to asses 
changes in phase transition by measuring the heat exchange associated with cooperative lipid 
phase transitions in model and biological membranes. One of the most important parameters 
to be obtained seems to be the change in the main phase transition temperature, which is 
the peak of the gel-to-liquid crystalline endotherm, Tm. A decrease in Tm suggests higher 
disorder of the hydrocarbon chains and, therefore, an increased fluidity of the membrane can 
be inferred [98]. Zhao et al. used DSC to determine the phase transition temperatures of MLV 
and SUV lipids under the influence of CEUs [80], while Speelmans and Pignatelo performed 
similar experiments using cisplatin[81] and methotrexate[82] respectively on MLVs. 
 
 
 
Figure 6 Structures adopted by phospholipids in aqueous media. Most phospholipids adopt only the first 
two phases, while some other such as DPPE form hexagonal phases.  Lβ and Lα (gel and liquid crystalline) 
states exists at low and intermediate temperatures respectively, while the inverted cylinder 
(hexagonal) HII state is found at high temperatures. Adapted from Seydel et al. (2002) [98]. 
Fluorescence measurements include a variety of methods that use fluorescence to 
determine a number of parameters. A few of these fluorescence methods will be described 
where relevant along this topic.  
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Fluorescence measurements are actually very useful in this field and versatile, allowing 
the evaluation of parameters such as membrane organization, permeability and fluidity as 
well as drug location in model membranes. The techniques are fairly simple and involve the 
coupling of a fluorescent probe to the drug or the membrane lipids, depending on the goal of 
the study. The fluorescence can then be followed through fluorescent microscopy or 
spectrometry [98]. 
Fluorescence anisotropy can be used to determine the size and shape of molecules, 
interactions between molecules and rigidity of many molecular environments, having been 
employed in the study of membrane fluidity [99, 100]. Fluorescence anisotropy is a 
phenomenon through which the light emitted by a fluorophore has different intensities along 
different axes of polarization. In other words, this is a method based on the photoselective 
excitation of fluorophores by polarized light. These preferentially absorb protons whose 
electric vectors are aligned parallel to the transition moment of the fluorophore. As a result, 
upon excitation with a polarized light, one is selectively exciting the fluorophores whose 
absorption transition dipole is parallel to the electric vectors of the excitation [100]. Emission 
occurs also with a polarized light through a fixed axis. The relative angle between these two 
axis determines the maximum anisotropy measure [100]. 
In a regular experiment using this method, the fluorescence intensities with the 
excitation polarizer aligned vertically while the emission polarizer is aligned vertically as well 
(Ivv) and horizontally (Ivh) are measured. Through the following equation, the anisotropy 
value, A, can be obtained: 
   
          
             
 
Where G is the grating factor, which is a correction factor for the polarization by the 
interior components of the fluorometer that is determined by 
   
   
 . Ihv and Ihh are the 
measured intensities with the excitation polarizer aligned horizontally while the emission 
polarizer is oriented first vertically and then horizontally, respectively [99, 100]. 
The anisotropy, A, depends on the fraction of fluorescent solute interacting with a 
macromolecule, in this case, an anticancer drug molecule, and on the rigidity of the 
complex[99]. In the paper by Martin et al., fluorescence anisotropy showed a decrease in 
membrane lipids order in the presence of 2-hydroxyoleic acid (2OHOA) [101]. 
Certain substances have the ability to decrease the intensity of fluorescence of a 
fluorophore. That process is called quenching, and the causing substance or molecule is a 
quencher. This is a very useful in membrane-drug interaction studies. Let’s suppose that the 
drug studied is coupled with a fluorophore that suffers quenching by a certain region of the 
hydrocarbon chains of the membrane’s phospholipids. The membrane is put in contact with 
the drug, which penetrates it. The fluorescence can be measured then. Depending on the 
amount of quenching the fluorophore suffered, it can therefore be determined how close to 
the quencher region of the hydrocarbon chain the drug partitioned to [98, 102]. Also to 
determine partition, fluorescence microscopy can be used and the fluorophore-drug complex 
can be visualized in the compartment it partitioned into. The same can be performed with 
confocal microscopy [98]. 
De Wolf measured the quenching doxorubicin bring upon itself when it self-associates and 
through this knowledge was able to determine that doxorubicin complexes dissociated and 
bonded to SUVs [87]. To test the effect of edelfosine on the membrane’s permeability, Busto 
et al. used LUVs containing a fluorescent substrate and added the drug to the medium. By 
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measuring the fluorescence on the outside of the vesicles it was possible to determine vesicle 
efflux caused by edelfosine and that the drug increased the membrane’s permeability [44]. Li 
performed similar experiments using doxorubicin on MLVs [85]. 
X-ray diffraction techniques (small angle, SAXS, or wide angle x-ray scattering, WAXS) are 
very useful to obtain information regarding the localization of the drug on the membrane and 
the conformational changes of the membrane. The principle behind it consists of comparing 
the electron density profile of untreated lipid membranes with the profile of lipid membranes 
under the effect of the drug [98]. If the sample is partially hydrated, probes are used and a 
coherent Bragg-like scattering can be obtained with reasonable resolution. The differences 
observed give information on the drug location within a bilayer, as well as on the structural 
changes that it caused to the membrane [98]. Pili and Bildstein used the techniques SAXS and 
WAXS to determine the effect of a hybrid anticancer drug made of squalene and gemcitabine 
on structure parameters at varying temperatures and on phase transition [77, 84]. Li and 
colleagues analyzed the  effect of doxorubicin on the packing of lipids using SAXS [85]. 
 
 
 
Figure 7 A schematic of a Langmuir Blodgett trough: 1. Amphiphilic monolayer 2. Liquid subphase 3. LB 
Trough 4. Solid substrate 5. Dipping mechanism 6. Wilhelmy Plate 7. Electrobalance 8. Barrier 9. Barrier 
Mechanism 10. Vibration reduction system 11. Clean room enclosure. 
DSC and x-ray diffraction techniques are often coupled with nuclear magnetic resonance 
(NMR) spectrometry, a technique that is also able to evaluate the effect of ligands (drugs in 
the case) on the membrane structure as well as its motional characteristics. NMR techniques 
provide detailed information about molecular conformation and ordering, and relaxation time 
measurements probe the amplitude and time scale of motions and allow interaction 
phenomena to be studied. Solid-state NMR allows a more direct approach to ligand–receptor 
interactions, normally with enhanced sensitivity, resolution and assignments, by specifically 
incorporating NMR isotopes (2H, 13C, 15N, 19F). Solid-state NMR can provide information on 
the orientational constraints of labeled groups in ligands and peptides caused by the spectral 
anisotropy of certain nuclei. Magic angle spinning (MAS) solid-state NMR methods have been 
applied to determine spin-coupled distances through dipolar coupling determinations, to high 
resolution (0.3Å) and chemical shifts to define the ligand-binding environment [98]. Jensen 
studied the effect of cisplatin on the phase behavior and conformation of lipid bilayers [93] 
and liposomes [94]. 
Fourier transform infrared spectroscopy (FT-IR) also provides organizational information 
on the lipid membrane but at a molecular level. The spectra are characterized by the 
wavelength of the maximum of the absorption signal and the width and intensity of the signal 
as a function of the direction of the polarized light beam. The analysis of the signals obtained 
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for the hydrophobic and hydrophilic regions of the phospholipids can give insight regarding 
intra- and intermolecular interactions. When amphiphilic drugs are added, local phase 
changes can be detected if the drug has interacted with the membrane, providing 
information regarding the phase changes [98]. Therefore, the orientation and degree of 
organization of substructures within the phospholipids can be assessed through this method, 
as well and the possibility of drug partitioning into the bilayer [98]. Therefore, FT-IR data can 
complement or even substitute the information that can be obtained through NMR [98]. FT-IR 
has been used, for example, to determine the effect of etoposide and cytarabide on the 
membrane structure of SUVs [83] and to study the changes in membrane structure and phase 
transition temperatures as well as the drug incorporation in lipid bilayers and MLVs suing 
CEUs [46, 91]. 
Circular Dichroidism also focuses on determining drug location and conformation on the 
membrane [98]. Li and Gallois used this technique to assess the partitioning of doxorubicin 
into LUVs [85, 95]. 
Lipid monolayer techniques are some of the most used techniques to study the effect of 
anticancer drugs on lipids of the membrane. Although the monolayer structure differs from 
the general structure of cell membranes (bilayer), it is thought that they provide an 
organized interfacial structure similar to that found in cell membranes. With this model, the 
tendency of drugs to accumulate in the interface of the membrane can be studied as well as 
its behavior there. Drug-monolayer interactions can be characterized by changes in the 
surface pressure, surface potential or binding [98]. Langmuir monolayers, which are basically 
monolayers constituted of only one molecule type, are often chosen due to the simplicity of 
preparation and control of the conditions, with main focus on surface pressure for example. 
Busto and colleagues were able to study the effect of edelfosine on Langmuir monolayers, 
namely the drug’s capacity of penetrating the monolayer [44]. There is also the Langmuir-
Blodgett (LB) monolayer, and its preparation involves the transfer of a Langmuir monolayer to 
a solid substrate in order to make highly ordered, ultra-thin, defectless films with 
controllable architecture, orientation and thickness [103]. Studies of these models were used 
to determine the adsorption of doxorubicin to the monolayer [89]. The monolayers are 
usually formed and analyzed in an apparatus called Langmuir-Blodgett trough, schematized in 
figure 7. 
Another method used to determine surface potential is electrophoretic light scattering 
(ELS). The principle of ELS is fairly similar to that of dynamic light scattering or DLS – a laser 
beam directed at a sample will produce a frequency or phase shift that depends on the 
dispersed particles’ mobility. While, in the case of DLS, Brownian movements are responsible 
for particle motion, in ELS that is caused by an oscillating electric field [102]. The ELS 
technique is mainly useful to determine the zeta potential of a particle. The zeta potential is 
the potential difference between the dispersion medium and the stationary layer of fluid 
attached to the dispersed particle [104].  
It is a good indicator of the magnitude of repulsive electrostatic interactions between 
particles, and as such can provide insight on molecule adhesion, flotation and, in membranes 
for example, rigidity [104]. Park et al. used this technique to determine particle size, 
polydispersity index and zeta potential of nanoparticles loaded with doxorubicin [105]. 
It is evident that different techniques can give different data that overlap amongst them.  
Determination of drug partition was for many years performed using the octanol-water 
partitioning method. However, it is being put aside due to its limitations compared to 
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partitioning into the membranes. In fact, the octanol-water partition coefficient has been 
proven to not always be the most accurate. Therefore, membranes are recently being used 
for this purpose and have demonstrated enormous discrepancy with the older method’s 
values. It appears that the octanol-water partition coefficient alone is unable to account for 
variations in biological selectivity, which might be related to, besides hydrophobicity, 
hydrogen-bonding substituents. 
Lipid vesicles are models that can replicate cellular conditions, since they present a 
curvature of the membrane like what is observed in cells, besides the possibility of being 
produced with components very similar to those existing in biological membranes. All of 
these extra parameters in regards to structure and composition, these models allow the study 
of other interactions besides hydrophobic, such as electrostatic interactions. Using lipid 
vesicles, the partition can be detected by simply coupling with spectroscopy, a method 
described above. Alternatively, HPLC could also be used depending on the constituents of the 
membranes. Appropriate columns, with, for instance, irreversively bound phosphatidylcholine 
are currently commercially available. 
Circular Dichroidism and FT-IR, as well as cyclic voltametry are other techniques are 
currently used for the determination of the partition of the drug. [98]. 
A few studies also contemplate the relative affinity of anticancer drugs to the membrane 
comparing with other drugs, such as neomycin. Burger and colleagues used the two-
dimensional thin-layer chromatography (2D TLC) to distinguish and separate the drugs 
regarding their affinity [96, 98]. 
 
1.3.2. Effect of anticancer drugs on biophysical parameters of model 
membranes 
 
The previous topic showed that model membranes are being considerably used in several 
research areas nowadays. Actually, contrary of what could be believed, using lipid 
membranes as models to study the behavior of cell membranes while interacting with drugs is 
not a new concept and has been the goal of numerous studies for more than 20 years [87, 
106-108]. However, since the membrane is such a complex structure, and there are many 
parameters involved in the study of its interactions with drugs, more information is still to be 
gathered. This field continues to be of high importance in the general overview of scientific 
and health-related research, as the understanding of the penetration and state changes in 
membranes as a result of its interaction with anticancer drugs could benefit the development 
of new and possibly more efficient drugs as well as provide higher amounts of base knowledge 
that could be used in other fields as well, like in nanotechnology [97]. 
Table 4 presents a summary of the main effects of different anticancer drugs on various 
model membranes as well as the techniques used to study them. 
It has been previously stated that the membrane’s lipid composition determines its 
characteristics as well as its behavior under different conditions. Consequently, it makes 
sense that the lipid composition of model membranes plays a similar role. Therefore, one of 
the most important aspects to have in mind in drug-membrane interaction studies is the lipids 
that constitute the model membrane. 
The most used lipids in these studies, according to table IV, seem to be derivatives of 
phosphatidylcholine (PC), such as dipalmitoyl phosphocholine (DPPC), dioleoyl 
phosphocholine (DOPC), palmitoyl oleoyl phosphocholine (POPC) and egg PC (EPC). 
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Phosphatidylcholine is, as previously stated, one of the major components of naturally 
occurring biological membranes, so the use of PC derivatives in model membranes promotes a 
proximity in the natural and artificial membranes’ characteristics, theoretically producing a 
model membrane that is more similar to a biological one, not only in structure but also in 
curvature and behavior when interacting with external substances, in the present case, 
anticancer drugs [50, 61]. Dimyristoyl phosphoglycerol (DMPG) and dipalmitoyl 
phosphocholine (DPPG) are also amongst the most used components of model membranes for 
similar reasons, being derivatives of an important and very simple phospholipid found in 
biological membranes, phosphatidylglycerol (PG) [50]. 
However, biological membranes naturally contain other molecules in lesser amounts that 
can also modulate its behavior. Important examples are sphingomyelin (SM) and cholesterol, 
which appear to have some importance in regulating the membrane’s stability and signal 
transducing properties [50, 51], and therefore are also used in drug-membrane interaction 
studies, whether it is in combination with each other [45] or as a part of model membranes 
made of a variety of lipids [46, 80, 85, 88, 90, 95, 108, 109]. Also, comparisons between 
single lipid models and mixtures allow the determination of the effect of specific lipids in 
drug-membrane interactions [97]. 
Other lipids that also appear in cell membranes in lower quantities, such as phosphatidic 
acid (PA) and phosphatidylinositol (PI) and its derivatives (phosphatidylinositol-1-phosphate, 
PIP, and phosphatidylinositol-2-phosphate, PIP2), are also used in some studies [87, 93, 95, 
108]. 
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Table 4 Overview of the state of the art regarding drug-membrane interaction studies – the effects of anticancer drugs on lipid model membranes. 
Anticancer Drug 
studied 
Drug Concentration 
Type of Model 
Membrane 
Composition 
(proportion) 
Technique pH Drug Effects (and location) on the membrane Refs. 
Squalene+Gemci
tabine 
7 mM MLVs DPPC SAXS; WAXS 7.4 -Penetration into the membrane. [77] 
SqGem/DPPC ratio = 0 to 
0.45 
Lipid Bilayers DPPC SAXS; WAXS 7.4 
-Formation of a bicontinuous cubic phase (between gel and fluid 
phases); 
-Drug partitions between the lipid acyl chains of the bilayer. 
[84] 
SqGem/DPPC ratio = 0 to 
0.45 
Lipid Bilayers DPPC DSC 7.4 -Higher lipid disorder – more fluidity. [84] 
1.4 mM 
 
Lipid 
Monolayers 
DOPC; 
DOPC:DSPC(1:1);DOPC
:DSPC:Chol(4.5:4.25:1
.25) 
BAM; 
Langmuir 
balance 
7.4 
-The drug penetrated in all the tested monolayers - smoother and 
faster for pure DOPC monolayer; slow for DOPC:DSPC due to 
closer packing of the lipids. 
-Presence of cholesterol improved drug adsorption to the 
membrane. 
[109] 
Edelfosine 
0-20  µM 
Lipid 
Monolayers 
POPC 
Langmuir 
balance; 
Fluorescence 
spectrometry 
7.4 
-Insertion into the monolayer at surface pressure above those 
supported by cell membranes; 
- Increased permeability of the monolayer. 
[44] 
Mole fraction 0; 0.025; 0.05; 
0.1; 0.2; 0.3 and 0.5 
Lipid 
Monolayers 
DPPC 
Langmuir 
isotherms 
7.4 
-Drug and lipid are miscible in monolayers; 
-Weak interactions and only at low levels of surface pressure. 
[86] 
Mole fractions 0.1, 0.3, 0.5, 
0.7 and 0.9 
Lipid 
Monolayers 
SM:Chol (2:1; 1:1;1:2) 
Langmuir 
isotherms 
6.5 
-Disorder of the lipid chains, more pronounced at lower 
proportions of cholesterol; 
-Increased permeability of the monolayer. 
[45] 
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Mole fractions 0.1, 0.3, 0.5, 
0.7 and 0.9 
Lipid 
Monolayers 
SM:Chol (2:1; 1:1;1:2) BAM 6.5 
-Alterations in the liquid and gaseous phases; 
-Alteration of the monolayer’s morphology, becoming 
inhomogeneous. 
[45] 
18  µM; 37,5  µM; 75  µM; 250  
µM. 
LUVs EPC 
Fluorescence 
spectroscopy 
7.4 -Increased permeability of the membrane. [44] 
CEUs 
Lipid/CEU molar ratios 0.1 
and 0.25 
MLVs 
DMPC; DOTAP; 
DOTAP:DMPC (1:1) 
FT-IR 7.4 
-No changes in fluidity of DMPC liposomes’ membranes; higher 
fluidity of DOTAP liposomes’ membranes at low drug 
concentrations; 
-Increased fluidity and permeability in DOTAP:DMPC monolayers. 
[91] 
Lipid/CEU molar ratios 5:1, 
20:1 and 50:1 
Lipid Bilayers 
DMPC;  
DMPC:Chol(7:3) 
FT-IR 7.5 
-Smaller and/or more branched R groups, sulfur atoms attached 
to the aromatic ring or low concentrations cause increase in 
fluidity; CEUs substituted in different positions lead to differences 
in fluidity; 
-Less disorder and fluidity in cholesterol-containing membranes. 
[46] 
Lipid/CEU molar ratios 5:1, 
20:1 and 50:1 
Lipid Bilayers DMPG FT-IR 7.5 -Increased fluidity, but less than for DMPC membranes. [46] 
Lipid/CEU molar ratios 5:1, 
20:1 and 50:1 
Lipid Bilayers POPC:DMPC (1:1) FT-IR 7.0 -Increased fluidity, similarly to that noted for DMPC bilayers. [46] 
Paclitaxel 23.4, 58.6 and 117 mM MLVs and SUVs 
DPPC; DPPC:Chol 
(9:1) 
DSC 6.5 
-Higher fluidity of the membrane; detection of a maximum 
solubility value of the drug; 
-Membrane containing cholesterol is more stable; 
-Drug located in the outer hydrophobic cooperative zone of the 
bilayer, i.e., region of carbon atoms C1–C8 in the acyl chain. 
[80] 
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23.4 and 234 mM MLVs and SUVs 
DPPC; DPPC:Chol 
(9:1) 
EPR 6.5 
-Higher fluidity and penetration of the DPPC membrane; 
-For the DPPC:Chol membrane, fluidity increases with 
temperature increase until Tm; from Tm up the opposite happens; 
-Drug located in the outer hydrophobic cooperative zone of the 
bilayer, i.e., region of carbon atoms C1–C8 in the acyl chain. 
[80] 
11.7, 23.4, 58.6, 117 mM SUVs 
DPPC; DEPC; DPPE; 
DSPC 
DSC  
-Little change observed for the DSC profiles of the DPPE and DSPC 
liposomes; noticeable change in the thermographs of DPPC and 
DEPC liposomes; 
-Paclitaxel localized in the outer hydrophobic cooperative zone of 
the bilayer, i.e, in the region of atoms C1-C8 of the acyl chain or 
binding at the polar head group of the phospholipid. 
[110, 
111] 
23.4, 58.6 and 117 mM [110-
112]; 5, 10, 300 and 600 nM  
[90];  
Lipid 
Monolayers 
DPPC; DEPC; DPPE; 
DSPC 
Langmuir 
balance 
 
-Drug penetration occurs rapidly until a solubilization limit. 
-Drug located in the outer hydrophobic cooperative zone of the 
bilayer, i.e., region of carbon atoms C1–C8 in the acyl chain. 
[90, 
110-
112] 
5, 10, 300 and 600 nM 
Lipid 
Monolayers 
Cancerous cervical 
lipid extract 
Langmuir 
balance 
 
-Drug penetration occurs rapidly until a solubilization limit for 
lower initial surface pressure values; for the higher value tested, 
rapid penetration of the drug is detected but after the maximum 
penetration desorption of the drug starts to occur gradually. 
[90] 
5, 10, 300 and 600 nM 
Lipid 
Monolayers 
Normal cervical tissue 
lipid extract 
Langmuir 
balance 
 
-Very different results compared to DPPC and cancerous cervical 
lipid monolayers; 
-At lower initial surface pressure values, equilibrium is achieved 
rapidly; at the highest initial pressure, membrane destabilization 
occurs. 
[90] 
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5, 10, 300 and 600 nM 
Lipid 
Monolayers 
DPPC:SM(8:2; 5:5; 
7:3) 
Langmuir 
balance 
 
-Paclitaxel penetration is  inversely proportional to the 
concentration of SM. 
[90] 
Doxorubicin, 
Pirarubicin and 
Daunorubicin 
1 µM LUVs 
PC:PA:Chol (75:5:20, 
60:20:20 and 52:3:45) 
Fluorescence 
measurements 
6 
-Permeability coefficient is the highest in LUVs which contain the 
lowest amount of cholesterol and PA; 
-Pirarubicin is more rapidly encapsulated than the rest; 
doxorubicin is the opposite. 
[108] 
Doxorubicin and 
Daunorubicin 
5 x 10 -4 M-1, 100 µM and µM LUVs 
PC:PA:Chol(95:5:0,75:
5:20,55:5:40, 
80:20:0,75:20:5, 
70:20:10,65:20:15,60:
20:20,55:20:25, 
50:20:30,45:20:35, 
and 40:20:40) 
Circular 
Dichroidism 
7 
-Doxorubicin: at low concentrations of PA, interaction is mainly 
through electrostatic forces; increases in PA amount lead to 
hydrophobic interactions predominating. 
-Daunorubicin: moves directly from the aqueous phase to the 
embedded site within the polar head region; 
-For both drugs, cholesterol concentration seems to produce no 
significant change in drug penetration. 
[95] 
Idarubicin and 
Idarubicinol 
5 x 10 -4 M-1, 100 µM and µM LUVs 
PC:PA:Chol(95:5:0,75:
5:20,55:5:40, 
80:20:0,75:20:5, 
70:20:10,65:20:15,60:
20:20,55:20:25, 
50:20:30,45:20:35, 
and 40:20:40) 
Circular 
Dichroidism 
7 
-Idarubicin: no or low PA causes embedding of idarubicin into the 
bilayer  as a monomer; high concentrations of PA induce 
embedding with formation of a complex of 2 or 3 molecules of the 
drug with molecules of PA and cholesterol; 
-Idarubicinol: penetrating as a monomer; 
-For both drugs, cholesterol is an essential factor for the 
penetration process. 
[95] 
Doxorubicin 
3.4 mM and 0.34 mM LUVs EPC:Chol (55:45) 
Confocal 
Microscopy 
7.5 -No observable membrane invaginations. [85] 
3.4 mM and 0.34 mM LUVs EPC:Chol (55:45) Circular 4 -Interaction drug-membrane is detectable regardless of drug [85] 
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Dichroidism and 
5 
concentration; 
-Doxorubicin’s complexed form seems to be the predominant 
form inside the liposomes. 
100  to 103 µM 
Lipid 
Monolayers 
PIP2 
Langmuir 
balance 
7.4 
-The drug penetrates into the monolayer; 
-Doxorubicin has similar affinity to this monolayer as neomycin. 
[87] 
5, 10, 25, 50, 100 and 200 µM Lipid Monolayer 
Pure lipids: PI; PIP; 
PIP2; DOPA; 
Cardiolipin; SAPA. 
Mixtures: 80% of 
DOPC+ 20% of each of 
the previous 
Langmuir 
balance 
7.4 
-More penetration in the PIP and PIP2 monolayers especially with 
DOPC (mixtures). 
[87] 
10  µM 
SUVs and 
Micelles 
Pure lipids: PI; PIP; 
PIP2; DOPA; 
Cardiolipin; SAPA. 
Mixtures: 80% of 
DOPC+ 20% of each of 
the previous 
Fluorescence 
spectroscopy 
7.4 
-More penetration in  PIP and PIP2 membranes, especially those 
containing also DOPC (similar as seen in the previous study. 
[87] 
20 and 40 nM 
Lipid 
Monolayers 
DPPC:Chol:PEG-PE  
(100:0:0;  100:20:0; 
100:0:4; 100:20:4) 
Langmuir 
balance 
7.4 
-In pure DPPC monolayers, doxorubicin penetrates creating a less 
condensed state; presence of cholesterol increased the rigidity of 
the membrane; 
-Drug localized between the DPPC acyl chains. 
[88] 
40 nM MLVs 
DPPC:Chol:PEG-PE  
(100:0:0;  100:20:0; 
DLS 7.4 
-Higher fluidity in all liposomes; 
-Presence of cholesterol reduced the aforementioned effect; 
[88] 
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100:0:4; 100:20:4) -Presence of PEG-PE lowers the penetration of the drug; 
-Drug localized between the DPPC acyl chains. 
1 x 10-5 M 
Lipid 
Monolayers 
Octadecanethiol:octa
decylamine (C18-
SH:C18NH2) and 
octadecanethiol:dihex
adecyl phosphate 
(C18-SH:DHP) 
Langmuir 
balance 
 
-Higher penetration for C18-SH:DHP than for  C18-SH:C18NH2 
monolayers. 
[89] 
1 x 10-5 M 
Langmuir–
Blodgett 
monolayers (on 
gold surface) 
C18-SH:C18NH2 and C18-
SH:DHP 
Cyclic 
Voltametry 
 
-Time of drug adsorption/partitioning on/into mixed monolayers 
is relatively short (~= 1 min); much faster adsorption/partitioning 
of doxorubicin into two-component monolayers. 
[89] 
1 x 10-5 M 
Langmuir–
Blodgett 
monolayers (on 
gold surface) 
C18-SH:C18NH2 and C18-
SH:DHP 
SERRS, SPR 
and QCM 
 
-Doxorubicin adsorbs at the monolayer surface but does not 
penetrate it; 
 -Drug located at the surface of the biomimetic film; the sugar 
moiety of the drug is expected to be away from the metal. 
[89] 
Cisplatin 
1 mM and 5 mM MLVs DOPS:DOPC (1:1) 2D TLC  
-Molar excess of glutathione prevents cisplatin-PS complexation. 
This also happens in cells. 
-Drug located in the inner leaflet of the membrane, in the polar 
head region. 
[96] 
10 and 30 mol% Lipid Bilayers 
PE 16.7%:PS 10.6%:PC 
9.6%:PA 2.8%:PI 1.6% 
and total pig brain 
NMR 7.4 
-Increase in fluidity; 
-Drug binds to the carboxyl groups in the polar head. 
[93] 
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lipid extract 58.7% 
10 and 30 mol% Liposomes POPS NMR 7.4 
-Cisplatin–POPS complex formation, possibly with cisplatin binding 
to one of the oxygen atoms of the POPS phosphate moiety. 
[94] 
25 to 250 µM LUVs 
DPPC; DPPG; 
DOPE:DOPC (1:1) 
Binding assays 
6 
and 
7.4 
-Interaction involved negatively charged phospholipids and only in 
buffers with low CI- concentration, indicating that aquated, 
positively charged cisplatin is involved. 
-Drugs binds to the polar heads of PS and PA. 
[81] 
5 mM MLVs 
DPPC; DPPG; 
DOPE:DOPC (1:1) 
DSC  
-Less fluidity but a high amount of bounds; 
-Drugs binds to the polar heads of PS and PA. 
[81] 
Methotrexate 
Drug-DMPC molar ratios of 
0.01 to 0.09 
MLVs DMPC DSC 7.4 
-Methotrexate conjugates increase membrane fluidity in a 
concentration-dependant way. 
[82] 
Tamoxifen 
1, 6, 9 and 15 mol% MLVs DMPC; DPPC DSC 7.4 
-Increased membrane fluidity; 
-Drug locates at the polar head region. 
[79] 
1, 6, 9 and 15 mol% MLVs DMPC; DPPC; DPPG FT-IR 7.4 
-For DPPG, higher fluidity is observed at low concentration of the 
drug (1 mol%); 
-Drug locates at the polar head region. 
[79] 
1, 6, 9 and 15 mol% MLVs DMPC DSC and FT-IR 7.4 
-Higher membrane fluidity with increase in drug concentration; 
-Drug partitions to the hydrophobic core of the bilayer. 
[78] 
Cytarabide 5 x 10-3 M SUVs  DPPC 
DSC, NMR and 
FT-IR 
7.4 
-Penetration into the bilayer observed; interactions with the 
choline group of DPPC; 
-Cytarabide ring and etoposide ring insert into the bilayer at the 
same depth and therefore can compete to penetrate it. 
[83] 
Etoposide 5 x 10-3 M SUVs DPPC 
DSC, NMR and 
FT-IR 
7.4 [83] 
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From Table 4 we gather that the effects of different drugs vary even when the same 
model membrane is used.  This is expected, since an assortment of very different drugs is 
currently being studied, with very different structures and conformations. 
This review focuses on some of the most used anticancer drugs for chemotherapy, namely 
doxorubicin, daunorubicin, cisplatin, paclitaxel, metothrexate and tamoxifen, and on few 
new drugs that seem promising and as a result have been widely studied ever since its 
discovery, such as ALPs, especially edelfosine, CEUs and a hybrid of gemcitabine and 
squalene. 
Even inside the same class of drug, for example, the anthracyclines, we find differences 
in the effects they exert on a model membrane. Doxorubicin and daunorubicin, for example, 
differ in terms of lipophilicity, and so they interact differently with the same membrane. In 
membranes with PC, PA and cholesterol, doxorubicin binds mostly through electrostatic 
forces, maintaining its dihydroxyanthraquinone moiety in the aqueous phase, while the more 
lipophilic daunorubicin requires mostly hydrophobic bonds, and as a result it partitions into 
different regions and through different processes [95]. More on this subject will be explained 
further ahead. 
Gemcitabine is a prodrug that has been studied for membrane interactions after being 
coupled with squalene, a natural lipid precursor of cholesterol biosynthesis. The resulting 
conjugate spontaneously self-assembles in water to form nanoparticles with an inverse 
hexagonal phase [97] and is apparently much more effective than the drug on its own [113]. 
The gemcitabine-squalene hybrid seems to generally increase DPPC membranes’ fluidity by 
causing disorder of the lipid acyl chains. It is able to penetrate both single lipid monolayers 
and bilayers [77, 84, 109], contrarily to gemcitabine that, at neutral pH, partitions between 
the aqueous medium and the lipid water interface, barely interacting with DPPC. The hybrid 
molecules insert between the lipid acyl chains while maintaining their polar head group 
anchored at the aqueous interface [97]. The gemcitabine-squalene bioconjugate induces the 
formation of an unusual inverse bicontinuous cubic phase over time, with a lipid order 
between those of the gel and fluid phases of DPPC, partly reminiscent of the “liquid ordered” 
phase Lo formed in saturated mixtures of PC or SM with cholesterol. When the temperature 
increased, a reversible transition to the fluid lamellar phase was observed. This influence has 
been correlated with the ability to alter the spontaneous curvature of the cell membrane 
leaflets, so this hybrid proves to be of relevance in the present context [84]. Edelfosine has 
been mainly studied using Langmuir monolayer techniques. It has been found that it also 
penetrates the monolayers, namely constituted of POPC and DPPC [44, 86]. This anticancer 
drug could increase the permeability of the membrane inserting in it also in LUVs made of 
EPC [44]. More complex models, such as lipid bilayers with different proportions of 
sphingomyelin and cholesterol, have provided not only information on the action of the drug 
over the membrane but also regarding the effect of cholesterol in the stabilization of the 
membrane when in contact with the drug. In fact, edelfosine was able to insert the bilayer, 
but this penetration was less effective in bilayers with higher amounts of cholesterol, which 
leads to believe that this molecules is able to stabilize the membrane and thus impair the 
penetration and general effects of edelfosine [45]. 
CEUs are a type of novel anticancer drug that are being exhaustively studied. There are a 
wide variety of these compounds and the difference in their properties resides in the 
composition and structure of their radical (R) group. Studies showed that 4-n-butyl CEU did 
not interact with DMPC liposomes, but that at low concentrations it did interact with DOTAP 
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liposomes or liposomes constituted of equal parts of DMPC and DOTAP, leading to believe that 
DOTAP could promote the insertion of 4-n-butyl CEU into the membrane [91]. 4-sec-butyl CEU 
however acts on both DMPC and DOTAP membranes leading to acyl chain disorder, although in 
different (but not quite defined) ways [91]. The effect of differences in R group was tested 
by applying CEUs with R groups of different lengths or branching on pure DMPC lipid bilayers 
and studied with FT-IR. CEUs composed of R groups with higher branching led to bigger 
decreases in Tm, which indicates that more branched CEUs fluidize the membrane better. 
The effect of the length of the R group was tested in a similar fashion and proved that 
smaller lengths lead to bigger decreases in Tm and therefore a more fluid membrane. The 
same effect was observed for CEUs possessing a sulfur atom bound to the aromatic ring. The 
effect of the position in which the CEU is substituted was also studied, and it was observed 
that the CEU substituted at the position four has a much higher influence in increasing the 
fluidity of the membrane and inserting in it than the one substituted at the position two [91]. 
The effects of 4-butyl CEU and 4-sec-butyl CEU were further tested with membranes 
constituted of DMPC with 30% of cholesterol. The presence of cholesterol markedly decreased 
the cooperativity of the lipid phase transition, but the effects on the lipid hydrocarbon chains 
were similar to those observed for DMPC systems in the absence of cholesterol [91]. 
Zhao and colleagues (2007) described the interactions of paclitaxel with MLVs and SUVs of 
DPPC in the absence and presence of cholesterol through DSC and EPR. They observed that 
the membrane became more flexible as a result of interaction with paclitaxel at a 
concentration up to 5%, which led to believe that there was a solubility limit for this drug in 
these membranes [80]. This concentration of the drug corresponded to the most stable mixed 
monolayers obtained, as inferred from the excess free energy of mixing [112]. The same 
models formed by DPPC and 10% of cholesterol produced similar results regarding the lipid 
disorder caused by paclitaxel and its insertion, but cholesterol seemed to stabilize the final 
membrane by strengthening the interactions between DPPC and paclitaxel, impairing further 
penetration of the drug [80]. Preetha et al. (2006), on the other hand, used lipid monolayers 
to study the effect of paclitaxel. Simple DPPC monolayers became more fluid after 
interacting with the drug, allowing it to rapidly penetrate the monolayer until a solubility 
limit was achieved. This is congruent with the findings of Zhao et al. (2007) [80, 114]. This 
data was then compared with the effect of paclitaxel on monolayers made of normal cervical 
lipid extract and of cancerous cervical lipid extract. Three initial surface pressures were used 
in the study – 10, 20 and 30mN/m. For monolayers constituted of cancerous cervical lipid 
extract, the first (and lower) two initial pressure values produced results no different than 
those found for DPPC monolayers.  However, at the highest initial value, 30mN/m, after a 
maximum of solubilization of paclitaxel into the membrane, there appears to be desorption 
of the drug from the monolayer. The normal cervical lipid extract monolayers presented very 
different kinetics of drug penetration. 
In this case, at 10 and 20mN/m, very rapid drug adsorption occurs and the equilibrium is 
achieved much faster than in the previous monolayer types. However, at 30mN/m the 
opposite occurs, the equilibrium being achieved after much more time than for the other 
monolayers, and beyond that point a progressive decrease in surface pressure is observed 
down to values even below zero, indicating membrane destabilization [114]. So, higher drug 
penetration was observed for DPPC monolayers compared to the other two. Comparing the 
two lipid extract monolayers, drug penetration was higher for the one formed by normal 
cervical lipids. This may be due to the different composition of the two lipid extracts. 
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Posterior quantification of these two lipid extract monolayers showed that cholesterol was 
1.5 times higher in amount in cancerous than in normal cervical tissue. Sphingomyelin (SM), 
phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), 
phosphatidylinositol (PI) and phosphatidylglycerol (PG) were also present in higher amounts in 
cancerous cervical tissue [114]. Cholesterol was found to reduce drug penetration when 
present in DPPC membranes [115]. Preetha and colleagues proved also that sphingomyelin 
prevented drug penetration. Consequently, it is possible to infer that the higher amount of 
both lipids in the cancerous cervical tissue and in the resulting extract creates a more rigid 
monolayer that impairs paclitaxel penetration, which would explain these results, and this is 
in agreement with a previous study by the same authors that actually showed that the 
cancerous cervical lipid extract monolayer was more rigid than the normal cervical lipid 
extract one [114, 116]. 
Doxorubicin is perhaps the anticancer drug studied using the widest variety of model 
membranes, but in all studies it was shown that interaction with the membranes occurred 
and that doxorubicin could actually penetrate lipid membranes, even using very different 
lipids in each study [85, 87-89]. Interestingly, once again, membranes formed of more than 
one component appear to produce more relevant results. SUVs and micelles studied by De 
Wolf and colleagues allowed the penetration of doxorubicin in membranes of PIP and PIP2 
and even more if these contained also DOPC, being the latter more physiologically relevant 
[87]. Similarly to what is observed for paclitaxel, the presence of cholesterol in DPPC:PEG-PE  
monolayers and MLVs decreases the drug penetration into the membrane; PEG-PE appears to 
have a similar effect, which might be related to its binding partly to the hydrophobic region 
and partly to the polar heads of the lipid membrane [89]. 
The studies by Speelmans (1994), Frézard and Gallois (1998) focused in comparing the 
effects of various anthracyclines derivatives on the membrane of LUVs encapsulating DNA, 
and therefore being one step closer to cells [95, 108, 117]. 
The permeation of the membranes by anthracyclines occurred in three steps: partition 
within the interfacial region of the bilayer, followed by diffusion through the hydrophobic 
core and lastly desorption from the interface on the opposite side. At physiological pH, these 
molecules could partition within the interfacial regions through electrostatic and hydrophobic 
interactions and then cross the hydrophobic core in their unprotonated form [97]. Studies 
performed at pH 5 showed that the protonated form was unable to cross membranes [108]. 
Fluorescence studies were used to compare the effect of doxorubicin, pirarubicin and 
daunorubicin on membranes of phosphatidylcholine (PC), phosphatidic acid (PA) and 
cholesterol at various molar ratios. It was shown that although all three penetrate into the 
membrane, the permeability is decreased as the amount of PA and/or cholesterol is elevated 
[95]. This is confirmed by other studies such as the one by Gallois and colleagues, which 
compared the effects of doxorubicin and daunorubicin with LUVs of similar constitutions and 
observed that at low molar ratios of drug/liposomes, both drugs interacted with the 
membrane as monomers. Doxorubicin displayed two types of interactions: electrostatic, in 
which the dihydroxyanthraquinone ring remained outside the bilayer, in the aqueous phase, 
and hydrophobic, in which the dihydroxyanthraquinone ring intercalated with the lipid acyl 
chains inside the bilayer. The proportions of these interactions depended on the composition 
of the membrane, which means that at low molar ratios between PA and doxorubicin, it binds 
to the membrane mainly through electrostatic interactions, remaining at the interface. When 
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this ratio increases, however, a hydrophobic interaction begins to prevail. Daunorubicin, 
being more lipophilic, displayed only hydrophobic interactions [95]. 
In general, the rate of uptake was the lowest for doxorubicin and the highest for 
pirarubicin, since it was the most hydrophobic and showed the highest pKa (highest 
neutral/protonated form ratio) [108]. The permeability coefficients were the highest for the 
lowest amounts of PA and/or cholesterol in the membrane [108], although cholesterol didn’t 
seem to exert as much as an important effect in this case as it does when the more lipophilic 
drugs idarubicin and idarubicinol are studied [95]. 
It is interesting to notice that a very limited number of model membrane types is chosen 
for the displayed studies. These types of model membranes were described previously. The 
specific choice of these, however, resides in a set of properties they possess and/or share 
with cells and that can therefore give credibility to the results. Lipid monolayers are used not 
only for their simplicity and ease of production, but mostly for the possibility of controlling 
all of the conditions surrounding them. Monolayers might not produce results that can be 
directly linked to cell membranes, but monolayer techniques provide a wide basic knowledge 
on the behavior and interactions of a desired lipid or set of lipids with desired drugs [97]. 
Micelles achieve similar results, although they are perhaps a slightly more accurate model 
due to lipid curvature. Liposomes, however, seem to be the most used models. This may be 
because they combine two of the main characteristics they share with cell membranes: a 
bilayered structure of phospholipids and a curvature that allows it to become a closed 
vesicle. Being so, they are most likely the models that are closest to the cell structure, and 
can therefore provide more biologically accurate data. MLVs and LUVs are the most 
frequently used. MLVs are the easiest to obtain and are constituted of a number of 
membranes that can be analyzed. LUVs are of especial importance, though, since the degree 
of curvature of their lipid membranes is the most similar to that of actual cell membranes 
[97]. 
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Chapter 2  
Aim 
The previous chapter described the state of the art in this field and as a result 3 main 
factors become evident: drug-membrane interaction studies are essential to the advance of 
pharmacology and medical science in general, but biophysical studies such as these are not as 
common as they should be; cells are complex, time-consuming and expensive models for this 
kind of study; membrane models such as liposomes can be a good alternative. As a result, 
there are two needs that arise - further investigation on drug-membrane interactions and the 
development of better models to perform them in. 
In this context, this work was designed to tackle both of these needs. The objective was 
to develop an innovative set of liposome formulations that can mimic the membranes of 
normal and tumoral cells and be henceforth used in biophysical studies to determine the way 
the anticancer drugs interact with biomembranes.  
For that purpose, two anticancer drugs were chosen for the study, daunorubicin and 
doxorubicin, since they are currently among the most used and the most effective and also 
due to the fact that they present similar structures except for one functional group, which 
leads to their use in different types of cancer. Four liposome models were designed, two to 
mimic the normal membranes (one with and one without cholesterol in its composition) and 
two to simulate a tumoral cell membrane (also one with and one without cholesterol). 
The effect of the two drugs in size, zeta potential, partition coefficient, membrane 
location and membrane fluidity were assessed for the four formulations and for a tumoral cell 
line. These biophysical studies may help to get a higher knowledge about complementary 
mechanisms of action at the lipid membrane level of these two anticancer drugs using simple 
but reliable membrane models. It is important to stress that the simplification of the 
membranes and therefore a complete control of such complex structures is critical to 
understand the interactions at the molecular level. Nevertheless, some of the interaction 
studies performed in the model membranes were also performed in tumor cell lines (MDA-MB-
231), to assess the degree of similarity regarding biophysical parameters and regardless the 
simplicity of the models. These studies in cells are a novelty and their development and 
standardization can be a big step ahead in membrane biophysics studies.  
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Chapter 3  
 
Materials and Methods 
The current chapter describes all the methodologies employed in this work for the study 
of anticancer drug-membrane interactions. The theoretical foundation behind each technique 
will be exploited as well as their practical application in the case of this study. The results 
obtained are shown and discussed in the next chapter.  
3.1- Drug Choice 
Daunorubicin and doxorubicin were chosen for the aforementioned studies. These are, as 
has been established in the introduction, two of the most frequently used chemotherapeutic 
drugs, being highly effective in a wide range of tumors [47]. It seems, therefore, like a good 
starting point to study drugs with a wide range of therapeutic and toxic effects as it can 
provide information that can be narrowed down to more specific inferences in future 
research. These two anthracyclines are very similar in structure except for one group, as is 
represented in figure 8. 
 
Figure 8 Chemical structures of doxorubicin, Dox (left) and daunorubicin, Dan (right). These two 
anthracyclines present almost identical structures except for an extra alcohol group in doxorubicin, in 
the figure represented in blue (Image from [118]). 
 
It is evident that the structures of the two drugs vary only in a single functional alcohol 
group that is present in doxorubicin but not in daunorubicin. However, while daunorubicin is 
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almost only used to treat acute leukemia, doxorubicin has a very wide range of application, 
being used in the treatment of non-Hodgkin’s and Hodgkin’s lymphoma, multiple myelomas, 
as well as lung, ovarian, gastric, thyroid, breast and pediatric cancers [119]. Also, although 
both drugs cause the same kind of side-effects (see Table 2), being the most concerning by 
far cardiotoxicity, it appears that these side effects are usually more severe when 
doxorubicin is used, and as such this drug could be considered more aggressive [120]. In fact, 
several cases of cardiomyopathy have been correlated with cumulative exposure to 
doxorubicin [120, 121]. 
So, these two drugs, although sharing the same mechanism of action and side effects, 
peak in antitumoral activity efficacy in different types of tumors and cause side effects with 
different levels of severity. In this context, it was thought that studying these two drugs and 
their interaction with the membrane specifically could be a way to justify these differences.  
 
3.2- Reagents 
DMPC (1,2-dimyristoyl-sn-glycero-3-phosphocholine), DOPC (1,2-dioleoyl-sn-glycero-3-
phosphocholine), DPPS (1,2-dipalmitoyl-sn-glycero-3-phospho-L-serine) and cholesterol were 
purchased from Avanti Polar Lipids Inc. (Alabaster, AL, USA), and daunorubicin and 
doxorubicin were obtained from Biovision Inc. (Milpitas, CA, USA) and used without further 
purification. DPH (l,6-diphenyl-l,3,5-hexatriene) and TMA-DPH (1-(4-
trimethylammoniumphenyl)-6-phenyl-1,3,5-hexatriene p-toluenesulfonate) were obtained 
from Molecular Probes (Invitrogen Corporation, Carlsbad, CA, USA). Methanol, chloroform, 
DMSO (Dimethyl Sulfoxide), Hepes Hemisodium Salt, Trizma Maleate and NaCL (Sodium 
Chloride) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). The cell 
medium RPMI 1640 with UltraGlutamine I and Hepes, trypsin-EDTA (ethylenediamine 
tetraacetic acid), PBS (phosphate-buffered saline), FBS (fetal bovine serum) and Trypan Blue 
were purchased from Gibco by Life Technologies (Invitrogen Corporation, Carlsbad, CA, USA). 
Drug solutions were prepared either with Hepes buffer (10 mM, pH 7.4) or Tris buffer (0.1 
M, pH 6.3). The ionic strength of Hepes buffer was adjusted to physiological conditions with 
NaCl (I = 0.1 M). The buffers were prepared using double-deionised water (conductivity 
inferior to 0.1 μScm-1). 
The medium used on the culture of MDA-MB-231 cells was RPMI 1640 with UltraGlutamine 
I and Hepes to which 5% of FBS was added. 
 
3.3- Liposome Models and Preparation  
3.3.1. Liposome Models 
Since our aim was to study the effects of the two anticancer drugs on both normal and 
tumoral membranes, membrane models for both cases were designed. For each case, another 
model was designed without any cholesterol content in order to help determine the influence 
of this molecule on the membrane itself and on the interaction studies. The prepared models 
and respective properties are shown in Table 5. 
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The normal membrane models were mainly composed of DMPC since PC is the biggest 
constituent of membranes. The model containing cholesterol was prepared with 25% of this 
lipid. The tumoral formulations were prepared using a mixture of DMPC (as main constituent), 
DPPS, to represent the exposed PS on the outer leaflet of the membranes of tumoral cells, 
and DOPC, which is an unsaturated phospholipid that is included to mimic the increase in 
fluidity observed for tumoral membranes [57, 60]. The lipid stechiometry used is also 
represented in table 5 and was decided taking into account what is found in the literature 
regarding the differential lipid content of cell membranes [50, 52-60]. 
Table 5 Membrane mimetic models designed for the present study, along with their 
composition and pH conditions. 
Model 
Lipid Composition (Molar 
Proportions) 
pH (Buffer) 
Normal DMPC 
7.4 (Hepes) 
Normal with Cholesterol DMPC:Chol (3:1) 
Tumoral DMPC:DOPC:DPPS (3:1:1) 
6.3 (Tris) 
Tumoral with cholesterol DMPC:DOPC:DPPS:Chol (3:1:1:1) 
The formulations were designed to be made up of LUVs 100 nanometers in diameter since 
these mimic the natural cell membrane’s curvature the best [75, 76]. 
 
3.3.2. Preparation 
Multilamellar vesicles (MLVs) were prepared by the classical method of the lipid film 
hydration [122]. The lipid solution, prepared using chloroform/methanol (3:2) as solvent, was 
evaporated to dryness with a nitrogen stream at 60ºC in a rotative evaporator. For the DPH 
and TMA-DPH labelled liposomes used in the fluorescence measurements, probe stock 
solutions were prepared using the organic solvents used for the lipids [chloroform/methanol 
(3:2)]. A specific volume of this solution was then added to the lipid in chloroform/methanol 
(3:1) at a lipid:probe molar ratio of 300:1, which is the ideal ratio for good signal detection 
without altering the membranes’ properties [100]. The mixture containing lipid and probe 
was then dried together. The resultant dried lipid film was dispersed with convenient buffer, 
either Hepes buffer or Tris buffer, and the mixture was vortexed to create MLVs. In order to 
obtain 100 nanometer unilamellar liposomes (LUVs), the mixture was extruded 10 times 
through polycarbonate filters with a pore diameter of 100 nm [123], at 60 °C (a temperature 
above the phase transition temperature of the lipids).  
 
3.4- Cell Culture 
3.4.1. Cell Type  
The cells used for the membrane location studies were the MDA-MB-231 cell line. These 
are from mammary gland adenocarcinoma and were chosen because breast cancer is one of 
the most frequent types of cancer to arise specially in women above 45 years of age, and still 
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has a very high mortality rate [6]. As such, the decision was made to use this cell type as the 
first one tested to validate the tumoral liposome models described above. 
 
3.4.2. Culturing Conditions 
MDA-MB-231 cells were cultured in 75 cm2 flasks at 37 ºC in an atmosphere with 5% CO2 
(Unitherm CO2 Incubator 3503 Uniequip; Planegg, Germany) in RPMI 1640 U1 with Hepes 
medium supplemented with 5% of FBS. Every three days, when cells were at approximately 
80% confluence, the old cell medium was removed, the cells were washed with PBS and 
detached from the surface using trypsin-EDTA, being the resulting cell suspension adequately 
dilluted onto a new flask with fresh medium. 
For the location assays, cells at 80-90% confluence were detached in the same way, but 
after ressuspension with medium they were centrifuged at 1500 rpm for 5 minutes so as to 
precipitate the biomass only. The supernatant medium was then removed and the cells were 
ressuspended in 3 mL of the same buffer used for tumoral liposome models, Tris buffer (pH 
6.3). Cells were labelled with DPH at a concentration of 1 mM or with TMA-DPH at 10.3 µM by 
incubation in the dark in ice for 1 hour. These concentrations of fluorophore were used since 
this protocol is still under optimization and these were the concentrations tested that 
allowed the acquisition of detectable signal. 
3.4.3. Cell Counting and Viability Assessment 
Cell counting was performed for each replica through the Trypan Blue Exclusion assay in 
order to make possible the determination of the volume of cell suspension to add to the 
samples so that their cell concentration was 1.6 x 105 cells/mL. 
 
 
 
 
 
 
 
 
 
 
In order to count the cells, a mixture of cell suspension and 0.4% Trypan Blue solution in 
PBS at a 1:1 proportion would be prepared and loaded onto a hematocytometer (Neubauer 
chamber) represented in figure 9 [124]. 
The cells in the areas marked with a “C” in figure 9 are counted, and the cell 
concentration in the suspension is therefore calculated by the following equation: 
        
           
                                                   Equation 1 
where n represents the number of cells counted in the four areas marked as “C”, 104 is the 
volume of those areas and Fd is the dilution factor, which in this case is 2. 
Cells were counted in the beginning of any methodology and after incubation with the 
fluorescent probes to ensure that the probes were not toxic to the cells and that the 
methodologies could proceed. Since the studied drugs are cytotoxic, cells were also counted 
Figure 9 Picture and representation of a Neubauer chamber. The cells on 
the chamber quadrants represented with “C” are counted. 
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after the execution of the techniques for a number of samples to ensure that the techniques 
were executed with enough live cells to produce viable results. 
 
3.5- Size and Zeta Potential Determination 
Before starting an actual biophysical study of drug-membrane interaction, the 
characterization of the model membranes that were prepared for this study is important to 
ensure that the preparation methods described in topic 3.3.2 were able to generate 
liposomes with the intended characteristics and as such ready to be applied to the 
biophysical methods ahead [125, 126]. 
The size and membrane surface charge of liposomes, the latter analysed through the 
determination of the zeta potential, were assessed through Dynamic Light Scattering (DLS) 
and Electrophoretic light Scattering (ELS), respectively. 
Light Scattering involves the incidence of a polarized laser beam on a sample and its 
scattering towards a detector placed at a 90º angle from the incident beam. Disperse 
particles suspended in a liquid medium undergo Brownian motions, which means that they 
are continuously moving, vibrating, translating and rotating. This causes the laser to be 
scattered at different intensities [125]. The scattered intensities fluctuate with time and 
provide information on the translational diffusion coefficient (Dt) of the particles. In a DLS 
apparatus, the signal obtained is processed by a correlator, and the fluctuations are 
interpreted by autocorrelation. It is through specific correlation of intensity fluctuations 
caused by the Brownian motions of the molecules in the sample along a period of time and 
with the aid of electrodynamics and theory of time dependent statistical mechanics that it is 
possible to obtain information regarding the structure and molecular dynamics of the 
particles in the medium [125, 126]. 
This method is one of the most used to determine the size of a particle in suspension as 
well as the range of particle sizes in said suspension. It is also useful for the determination of 
the surface charge via zeta potential, which is a measure of the electrical potential of the 
double layer at the interface between the dispersed medium and the stationary fluid adhered 
to the dispersed particle, and thus it gives us the information of the membrane surface 
behaviour in terms of charge [127, 128]. 
Ultimately, this technique was used to confirm if the prepared liposomes were 
approximately 100 nanometers in diameter, and if the surface charge was close to neutral in 
the normal models and negative in the tumoral models. For that purpose, samples for each 
model at a lipid concentration of 500 µM in the respective buffer were used. To determine if 
the chosen drugs had effect on liposome size and charge, samples with liposomes from each 
model at a lipid concentration of 500 µM were prepared with increasing concentrations of 
each drug, namely 5, 40 and 75 µM, and analysed through DLS (ZetaPALS BrookHaven 
Corporation Instruments; Software: PALS Zeta Potential Analyser v.5, Brookhaven 
Instruments; Holtsville, NY, USA). The assays were performed three times independently. 
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3.6- Biophysical modifications of the membrane 
The membrane structure is very important not only because of membrane permeability 
and interaction with exogenous molecules but also due to the action of endogenous molecules 
attached to the membrane (proteins, receptors, channels) and the molecular mechanisms 
involved in pharmacological effects exhibited by a variety of drugs [92, 93, 156]. 
Experimental work on membrane mimetic systems has demonstrated that their structural 
properties are strongly affected by membrane associated molecules. Many drugs are able to 
directly or indirectly influence cell membrane properties. For instance, interactions between 
proteins and phospholipids or the formation of complexes between ligand molecules and 
phospholipids or sterols can lead to disruption of the membrane so that it becomes highly 
permeable [129]. Some compounds can actually affect the fluidity of membranes, and some 
examples can be found in Chapter 1, Table 4 [46, 78-82, 84, 88, 91, 93, 94]. Additionally, 
changes in membrane fluidity can affect receptor and enzyme activity and influence the 
ability of drugs to pass through the membrane, which in turn can affect their efficacy. 
The importance of studying the action of anticancer drugs in the biophysical properties of 
the membrane is not limited to the understanding of their therapeutic effects but also to the 
elucidation of their side effects. A single biophysical method is not sufficient for a detailed 
analysis of the complexity of membrane dynamics and thermodynamics in the absence and 
presence of drug molecules. 
In this context, the next topics present several techniques that when combined provide a 
detailed description of the membrane biophysical changes resultant from the actions of 
drugs.  
3.6.1. Membrane partitioning    
The first step for the study of the interaction of drugs with membrane models should be 
the determination of the partition coefficient, which characterizes the extent of the 
interaction of a drug with a micro-heterogeneous system in a quantitative manner. Every 
bioactive compound needs an adequate balance between liposolubility (solubility in 
membranes) and hydrosolubility (solubility in blood and cytosol) and this balance is often 
expressed by the partition coefficient. The partition coefficient is therefore a key aspect for 
understanding the pharmacokinetics and pharmacodynamics of drugs, since it is associated 
with their passive permeation into or across membranes to access their sites of action [130], 
which in turn has implications in their therapeutic effects [129]. Additionally, the partition 
coefficient can be useful to predict toxic effects that arise from the bioaccumulation of drugs 
in tissues [130]. 
The partition coefficient (P) is defined by the ratio at equilibrium of the drug 
concentration in the organic phase and the concentration of the same drug in the aqueous 
phase [129]: 
  
             
           
               Equation 2 
The partition coefficient in the octanol/water system (KO/w) is the most commonly used 
parameter for determining the lipophilicity of a compound [131-133]. This biphasic mixture is 
widely used as a standard system mainly because it was the first system to be developed for 
the determination of the partition coefficient. Despite its successful application in drug 
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design, the octanol/water system may be an oversimplification and has been often seen as 
inadequate since an isotropic medium bears little similarities to biomembranes [129, 133], 
especially if we take into account that the organic phase in this system, octanol, lacks the 
amphiphilic nature of phospholipids, which have hydrophilic head groups and hydrophobic 
acyl chains [131-134]. Consequently, the Ko/w does not take into account the electrostatic 
interactions of compounds with the organic phase and provides information only on the 
hydrophobic interactions with the aqueous phase. The fact that more than 60% of the 
marketed drugs are ionisable (which includes the ones in this study, daunorubicin and 
doxorubicin [95]) makes the use of Ko/w  somewhat unreliable [135]. Finally, the relative toxic 
nature of octanol also dictates the need to use less pollutant alternative systems for partition 
coefficient determination [131]. 
Liposomes and micelles can advantageously replace octanol/water systems due to their 
anisotropic nature and their lipid ordered structure similar to that of natural membranes, and 
also by the possibility of studying the influence of electrostatic interactions in the partition 
phenomenon. Thus, the determination of the partition coefficient in liposomes or micelles/ 
water systems (Kp) gives more reliable data regarding the drug-membrane interactions, being 
these lipid model systems able to mimic the diverse membrane environments, from the polar 
surface to the lipophilic core. 
Some Kp determination methods in membrane model/aqueous systems involve phase 
separation while others don’t. Since phase separation is laborious and may cause equilibrium 
perturbation, the method selected to evaluate the lipophilicity of the anticancer drugs 
studied in the course of this work doesn’t involve phase separation. The quantification 
analysis was performed by derivative spectroscopy that will be further described in the next 
subchapter. 
i. Derivative spectroscopy 
For most of the cases, the partition coefficient of a molecule between a lipid and an 
aqueous phase can be evaluated by UV-Vis spectrophotometry as long as there is a difference 
in an absorbance parameter of the partitioning molecule (e.g., molar absorptivity, ε, and/ or 
wavelength of maximum absorbance, λmax) when in aqueous solution and after incorporation 
into the membrane [131-133, 136]. Therefore, it is possible to calculate Kp of a drug as long 
as its incorporation in the membrane leads to a change in the λmax in the order of 5-10 nm, 
and/ or a change in the ε between the two solvents (≥ 10%). The difference in the wavelength 
of maximum absorption in the presence of liposomes in relation to absorption maximum in 
buffer solution can also provide information about the distribution of the drug between the 
aqueous and lipid phase. Indeed, batochromic deviations (λmax deviations for higher 
wavelengths) are indicative of decrease of polarity in the drug’s surroundings and indicates 
an incorporation of the investigated compounds into the hydrophobic part of the lipid bilayer 
[137]) whereas hypsochromic deviations (λmax deviations for lower wavelengths) are indicative 
of the presence of the drug in a more polar microenvironment [137]). The use of UV-Vis 
spectrophotometry has plenty advantages, not only because most compounds have easily 
measurable spectroscopic properties, which depend on the chemical nature of the medium 
and are proportional to the concentration of compound at each stage, but also because the 
sensitivity of this technique allows the use of concentrations similar to those found in natural 
systems [138]. 
 Assessment of Anticancer Drugs’ Effects on Membrane Biophysical Properties using Model Membranes 
 
42 
 
Given the definition of the partition coefficient and the conditions under which the law of 
Lambert-Beer is applied, the absorbance of a solution containing a certain concentration of 
drug (Abs), that is distributed between the lipid (l) and aqueous (w) phase, can be related 
with Kp according to Equation 3 [136, 139]: 
   
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where AbsT, Absw and Absl correspond to the total, aqueous and lipid absorbance of the 
compound, respectively, Kp is the partition coefficient (dimensionless), [L] the lipid 
concentration (molL-1) and Vφ the lipid molar volume (Lmol
-1). 
Despite the apparent simplicity of Equation 3, its application is limited to systems with 
low scattering of light, such as micellar/aqueous systems. However, especially in cases where 
liposomes are used as membrane models, the presence of microstructures of heterogeneous 
sizes causes light scattering [132, 136, 140, 141], particularly at wavelengths below 300 nm, 
which results in a decrease of the light that reaches the detector. The spectroscopic 
interference of light scattering and the absorbance produced by the microstructures will turn 
the analysis of changes in the absorbance of the drug upon partition into a difficult task. To 
eliminate the background signal intensity caused by the vesicles, the absorption spectra of 
vesicle suspensions (references) with the same lipid concentration as the samples are 
measured and these spectra are subtracted to the correspondent sample spectra. However, 
even if the suspensions in the samples and references are prepared to contain the same 
amount of lipid vesicles, the counterbalance of the sample and reference beams is always 
incomplete being usually difficult to cancel completely the effects of the strong background 
signals, to obtain a flat and zero-level base line. The problem of the background interference 
of the medium due to light scattering of the vesicles is only eliminated by the use of 
derivative spectrophotometry (in order to wavelength, λ). In this context, the derivative 
spectrophotometry for the calculation of Kp is advantageous because it allows the elimination 
of interference caused by organized systems (difficult to cancel in zero-order 
spectrophotometry), without the need to employ techniques of phase separation. 
Furthermore, the derivative analysis of the spectra leads to a better resolution of overlapping 
bands [136, 140, 142]. 
The calculation of Kp by derivative spectrophotometry is based on an equation similar to 
Equation 3 [136, 143]:  
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The partition coefficients are then calculated by fitting Equation 4 to experimental 
derivative spectrophotometric data (D vs. [L]) through a nonlinear regression method where 
the adjustable parameters are Dl and Kp. 
Even with the aforementioned advantages of derivative spectroscopy, the overall analysis 
of spectra required for Kp determination is a time consuming process that involves many 
steps. Therefore, a friendly-use application for Microsoft Excel® created by Doctor Cláudia 
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Nunes, the Kp Calculator, was used during the course of this study to completely overcome 
this drawback.  
To assess the Kp values of all liposome models described, samples containing a fixed drug 
concentration of 40 µM and increasing concentrations of lipid (100, 200, 300, 400, 500, 600, 
700, 800, 900 and 1000 µM) were prepared. 
The therapeutic drug concentration of daunorubicin is 25.5 µM [144] and of doxorubicin 
about 29.4 µM [145]. In this study, most conditions were maintained as close as therapeutic 
conditions as possible. However, in the case of the drug concentrations used in research, 
concentrations often have to be adapted to the equipment’s sensitivity, and the drug 
concentration was chosen to be 40 µM since it has been proven to be an ideal concentration 
that allows good detection in previous published [146, 147] and unpublished work [148] using 
other drugs, and also produced the same good results when different concentrations were 
tested using daunorubicin and doxorubicin by MSC Catarina Alves and the author of this work. 
Identical samples without any drug content were also prepared to serve as references and 
allow the removal of some of the noise caused by micro scattering associated with the 
liposomes. Samples containing only drug at 40 µM were also prepared. All of the samples 
were incubated for 30 minutes at 37ºC. After that time their absorption spectra were 
recorded at physiological temperature (37ºC) in 96-well plates in a UV-Vis spectrophotometer 
(BioTek Synergy HT, Software: Gen 5, BioTek Instruments, Inc., Winooski, VT, USA). After 
measurements, each reference spectrum (background) was subtracted from the 
correspondent sample spectrum to obtain corrected absorption spectra. Derivative spectra 
were calculated using the Savitzky–Golay method [149] in which a second-order polynomial 
convolution of 13 points was employed. This was performed according to the Nature protocol 
by Magalhães et al. [150]. Three independent assays were performed. 
 
3.6.2.  Membrane location 
For compounds whose target sites are membranes or that interact at the membrane level, 
the orientation and location in the membrane are relevant parameters describing their 
effects. The study of membrane location thus allows a deeper understanding of the mode of 
action of drugs, contributing to the development of new types of drugs, more potent, more 
selective and with fewer side effects. 
In the case of this study, indirect methods of determining the membrane location of a 
compound will be used. These require the presence of a foreign compound that is normally a 
fluorescent probe included in the membrane. This probe works as a reporter and if any 
changes are observed on the fluorescence of this probe, those changes can be then related to 
the location of the drug. For example, if the molecular location of a probe within membranes 
is known with certainty, the deactivation of the probe’s fluorescence (also known as 
fluorescence quenching) induced by a drug can be used to reveal the location of the drug in 
the membrane [131, 143, 151, 152]. 
i. Steady-state fluorescence quenching 
In this study, the membrane location of drugs was assessed by fluorescence quenching of 
membrane bound extrinsic fluorophores (fluorescent probes). These fluorophores, usually 
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amphiphilic molecules, whose membrane location is known and well characterized, emit 
constant fluorescence in situations where there is no interference with their environment. 
However, when a drug partitions into the membrane, it can have a location close to the 
fluorophore and induce a decrease in its emitted fluorescence.  
Consequently, the decrease in the emitted fluorescence, also known as fluorescence 
quenching, of a membrane bound fluorophore provides a measure of its accessibility to the 
drug (quencher) and can be related with the concentration of the quencher [Q] by the Stern-
Volmer equation (Equation 6) [100]: 
 QK
I
I
SV1
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                   Equation 6 
where I0 and I are, respectively, the corrected fluorescence intensity of fluorophores in the 
absence and presence of drug and KSV is the Stern-Volmer constant. 
Plotting the values of corrected fluorescence intensities (I0/I-1) as a function of drug 
concentration ([Q]) a linear relationship is obtained, where the slope is the Stern-Volmer 
constant (KSV). 
The corrected fluorescence intensities used on Equation 6 were the result of a previous 
correction of the fluorescence values to eliminate the inner filter effect. The inner filter 
effect occurs when the drug absorbs at the wavelength of excitation of the fluorophore and 
decreases the effective intensity of the exciting light beam decreasing the measured 
fluorescence intensity. Since the absorption increases with the increase of the quencher 
concentration, this induces an apparent quenching and increases the values of the Stern-
Volmer quenching constants obtained from steady-state experiments. Therefore, 
fluorescence intensities should be corrected to eliminate this apparent quenching by 
Equation 7 [153]: 
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where Icorr is the corrected fluorescence intensity, I the experimental fluorescence and AQ and 
AF are the absorbance of the sample in the absence and presence of the quencher, 
respectively. 
ii. Fluorescence Quenching Mechanism 
There are two kinds of mechanisms responsible for fluorescence quenching [100, 154]: 
a) Static quenching: in static quenching a non-fluorescent complex is formed between the 
fluorophore and the quencher. When this complex absorbs light it immediately returns to the 
ground state without emission of any photon; 
b) Dynamic or collisional quenching: in the case of collisional quenching, the quencher 
must diffuse to the fluorophore during the lifetime of the excited state. Upon contact, the 
fluorophore returns to the ground state, with emission of a photon. In general, quenching 
occurs without any permanent change in the molecules, that is, without chemical reaction.  
Static and dynamic quenching can be distinguished by their differing dependence on 
temperature, viscosity and lifetime measurements [100]. The most effective way to 
distinguish the type of quenching is by lifetime measurements, and if the quenching process 
has a dynamic nature it will occur an equivalent decrease in fluorescence intensity and 
lifetime [100, 154]: 
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                         Equation 8 
where I0, τ0 and I, τ are respectively, the corrected fluorescence intensity and lifetime of the 
fluorophore in the absence and presence of the quencher. The decrease in lifetime occurs 
because quenching is an additional rate process that depopulates the excited state. Thus, in 
cases of collisional quenching the graphical representation of the values of fluorescence 
intensity (I0/I-1) or lifetime (τ0/τ-1) as a function of the concentration of the drug ([Q]) 
originates a linear fit in which the slope corresponds to the Stern-Volmer constant (KSV) that 
in this case is also called dynamic constant (KD). 
In the case of the static quenching, occurs the formation of a non-fluorescent complex 
between the fluorophore and the drug and thus the residual detectable fluorescence 
corresponds to the fraction of non complexed fluorophores. The fraction of fluorophore 
molecules that are not complexed by the drug remains undisturbed, and consequently the 
lifetime of the excited state remains also constant [100]: 
10 

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                   Equation 9 
iii. Deviations from the linear Stern-Volmer plots 
When the Stern-Volmer plot (I0/I -1 as a function of [Q]) is linear this indicates that only 
one type of quenching occurs. However, deviations from the linearity may also occur [100, 
154]. 
The negative deviations correspond to non-linear Stern-Volmer plots with a downward 
curvature towards the x-axis and may indicate the presence of fractions of fluorophore with 
different accessibility to the quencher, i.e., fractions that are not exposed together with 
fractions that are more accessible [100]. This negative deviation of Stern-Volmer plots is 
especially common in proteins. Indeed, proteins usually contain several tryptophan residues 
that work as fluorophores and are positioned in distinct environments. Each residue can be 
differently accessible to quencher. Hence one can expect complex Stern-Volmer plots, and 
even spectral shifts due to selective quenching of exposed versus buried tryptophan residues. 
The positive deviations correspond to non-linear Stern-Volmer plots with an upward 
curvature and are frequently observed when the extent of quenching is large and can be 
attributed to problems of distribution of the quencher and/ or the fluorophore [100]. Two 
models can explain this deviation: combined static and dynamic quenching and the sphere of 
action model [100]. 
In the case of this particular study, combined static and dynamic quenching might be the 
most adequate explanation. In many instances the fluorophore can be quenched both by 
collisions and by complex formation with the same quencher, translated by the following 
equation [100]: 
   20 )(1 QKKQKK
I
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SDSD                   Equation 10 
where I0 and I are, respectively, the corrected fluorescence intensity of fluorophores in the 
absence and presence of the quencher; [Q] is the concentration of the quencher and KD and 
KS are respectively the Stern-Volmer constants for dynamic and static quenching. For 
simplicity, Equation 10 can be re-written as follows: 
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A plot of (I0/I -1)/ [Q] versus [Q] yields a straight line with an intercept of KD + KS and a 
slope of KSKD (Figure 10). 
Moreover, the efficiency of the quenching or the accessibility of the fluorophores can also 
be assessed by the calculation of the bimolecular quenching rate constant [100]: 
 q 
 S 

            Equation 12 
If the quenching is known to be dynamic, the Stern-Volmer constant will be represented 
by KD, otherwise this constant will be described as KSV. Diffusion-controlled quenching 
typically results in values of near 1 x 1010 M–1s–1. Values of Kq smaller than the diffusion-
controlled value can result from steric shielding of the fluorophore or a low quenching 
efficiency. Apparent values of Kq larger than the diffusion-controlled limit usually indicate 
some type of binding interaction. 
 
Figure 10  Positive deviations to the Stern-Volmer equation and alternative models of linearization. 
Adapted from [100]. 
iv. Fluorescence probes 
Fluorescence probes contain fluorophores groups that allow obtaining a great variety of 
information through analysis of their excitation and emission spectra, their fluorescence 
quantum yield and the lifetime of the excited state and their polarization [129, 155]. The 
information reported by a probe inserted into a membrane (natural or model membrane) can 
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be used in the evaluation of membrane fluidity, the location of molecules in the membrane, 
intracellular ionic concentrations and membrane potential, among others [156]. 
Currently, there is a wide range of compounds used as fluorescence probes in several 
studies. In this work, the fluorophores chosen for assessing the membrane location of 
daunorubicin were DPH and TMA-DPH. TMA-DPH, contains a DPH phenyl ring located within 
the hydrophobic acyl chains of the membrane phospholipids and a cationic group, that 
anchors the probe to the polar headgroups of the phospholipids [157, 158]. Therefore, TMA-
DPH reports to the interfacial region of lipid membranes, while DPH provides information 
regarding the hydrophobic area of the membrane [157-159].  
v. Time-resolved fluorescence quenching 
Time-resolved measurements are widely used in fluorescence spectroscopy, particularly 
for studies of biological macromolecules and increasingly for cellular imaging [100]. 
Time-resolved measurements provide more information than the available from the 
steady-state data. One of the examples of the necessary use of time-resolved measurements 
is to distinguish between static and dynamic quenching using lifetime measurements [100, 
154]. Lifetime measurements are thus important, as they determine the time available for 
the fluorophore to interact with or diffuse in its environment, and hence the information 
available from its emission [100, 154]. 
There are essentially two types of methods for measuring fluorescence lifetimes that are 
in widespread use today: the time-domain and frequency-domain methods.  
In time-domain or pulse fluorometry, the sample is excited with a pulse of light. The 
width of the pulse is made as short as possible, and is preferably much shorter than the decay 
time τ of the sample. The time dependent intensity is measured following the excitation 
pulse, and the decay time τ is calculated from the slope of a plot of log I(t) versus t, or from 
the time at which the intensity decreases to 1/e of the intensity at t = 0 [100, 154].  
The alternative method of measuring the fluorescence lifetime is the frequency-domain 
or phase-modulation method, which was the one used in this work. In this case, the sample is 
excited with intensity-modulated light, typically sine-wave modulation (Figure 21). The 
intensity of the incident light is varied at a range of frequencies, usually 10-250 MHz. Its 
reciprocal frequency is comparable to the reciprocal of decay time τ [100, 154]. When a 
fluorescent sample is excited in this manner the emission is forced to respond at the same 
modulation frequency. The lifetime of the fluorophore causes the emission to be delayed in 
time relative to the excitation, shown as the shift to the right in figure 11. This delay is 
measured as a phase shift (φ), which can be used to calculate the decay time. The phase 
shift and modulation of the emission depend on the relative values of the lifetime and the 
light modulation frequency. The emission occurs at the same frequency as the excitation. 
Because of the loss of electron energy (Stokes’ shift) between excitation and emission, the 
emission waveform is demodulated and phase-shifted in comparison to the excitation. Thus 
the demodulation ratio (mω) and phase-angle shift (φ) constitute two separate observable 
parameters that are both directly related, via a Fourier transformation, to the initial 
fluorescence intensity and lifetime, τ, for a population of fluorophores [100, 154]. 
The shape of the frequency response is determined by the number of decay times 
displayed by the sample. If the decay is a single exponential, the frequency response is 
simple. One can use the phase angle or modulation at any frequency to calculate the 
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lifetime. For a single-exponential decay, the phase and modulation are related to the decay 
time (τ) by [100, 154]: 
t tan                 Equation 13 
and 
2
1
22 )1(

 m                     Equation 14 
where ω is the modulation frequency in radians/s and mω is the demodulation ratio of the 
emission. The origin of the phase shift and demodulation can be understood by considering 
the time-dependent excitation intensity and the time of intensity decay of the fluorophore.  
Most samples of interest display more than one decay time. In this case the lifetimes 
calculated from the value of φω or mω, measured at a particular frequency, are only apparent 
values and are the result of a complex weighting of various components in the emission. For 
such samples it is necessary to measure the phase and modulation values over the widest 
possible range of modulation frequencies. 
When the fluorescence decay of a fluorophore is multi-exponential, the lifetime is 
defined by [154]: 
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                Equation 15 
where fi  is the fractional contribution of component i to the total lifetime. 
 
Figure 11  Frequency-domain lifetime measurements. The ratios B/A and b/a represent the modulation 
of the emission and excitation, respectively. In this example the assumed decay time is 5 ns and the 
light modulation frequency is 80 MHz. Adapted from [100]. 
In Figure 12, is shown an example of a frequency domain lifetime measurement, 
performed in a previous work by Doctor Cláudia Nunes, on a suspension of LUVs of DPPC, 
labelled with TMA-DPH, upon addition of a NSAID (Piroxicam). From the variation of phase 
angle and modulation as a function of frequency (Figure 12 A), is possible to obtain the 
lifetime values, considering the discrete components and their contribution to the 
fluorescence. Additionally, the residue of adjustment for the multi-exponential model can be 
seen (Figure 12 B), and a distribution around zero shows a good fit for the phase angle and 
modulation.  
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The curve fitting is performed, by the least-squares method, in the frequency domain, 
i.e. directly using the variations of the phase shift φ and the modulation ratio M as functions 
of the modulation frequency. 
 
Figure 12 (A) Frequency-domain data for a double exponential decay obtained from LUVs of DPPC 
labelled with TMA-DPH after incubation with Piroxicam. The phase angle increases and the modulation 
decreases with increasing modulation frequency. (B) Residue model fit representing the small deviations 
between the theoretical multi-exponential fit and the experimental data. 
Usually phase data and modulation are analysed simultaneously, being the reduced chi 
squared (χ 2) given by [154]: 
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where N is the total number of frequencies. In this case, the number of data points is twice 
the number of frequencies, so that the number of degrees of freedom is υ = 2N – p (p = 
number of fitted parameters). The subscript c is used to indicate calculated values for 
assumed values of fi and τi, and σф and σM are the uncertainties in the phase and modulation 
values, respectively. 
In order to assess the quality of the fit is essential to observe the χ 2, whose value should 
be close to 1 for a good fit. Acceptable values are in the 0.8–1.2 range [100, 154]. Lower 
values indicate that the data set is too small for a meaningful fit and higher values are 
caused by a significant deviation from the theoretical model (e.g. insufficient number of 
exponential terms). Systematic errors (arising for instance from radiofrequencies interfering 
with the detection) can also explain higher values. 
For these studies, DPH- and TMA-DPH-labelled liposomes were incubated with various 
concentrations of the drug daunorubicin. Samples contained a fixed concentration of lipid of 
500 µM and increasing concentrations of daunorubicin (0, 5, 10, 15, 20, 25, 40 and 75 μM). 
Before fluorescence measurements, the resulting suspensions were incubated for 30 minutes 
at physiological temperature (37ºC) so that the drug could reach the partition equilibrium 
between the lipid membranes and the aqueous medium. Fluorescence measurements were 
carried out at a controlled temperature for each pH value of 37 °C, at excitation and 
emission wavelengths defined as 357 nm and 429 nm, for the DPH probe, and 359 nm and 429 
nm, for TMA-DPH. Fluorescence steady-state measurements were performed in a 
spectrofluorimeter (Jasco FP 6500, Software Spectra Manager, Jasco Analytical Instrumments, 
Easton, MD, USA) ) equipped with a constant temperature cell holder. All data were recorded 
in a 1 cm path length cuvette. For each measurement, fluorescence emission was 
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automatically acquired during 30 s. Fluorescence intensity values were corrected for inner 
filter effects at the excitation wavelength [153]. The same measurements were performed 
using the same samples in a plate-reading spectrofluorimeter (BioTek Cytation 3, Software 
Spectra Manager, BioTek Instruments, Inc., Winooski, VT, USA), in order to compare results 
and validate this method, since the plate reader is a much easier and faster method that 
could facilitate future studies. The same measurements were performed using cells by 
preparing samples at the same concentrations of daunorubicin with a steady concentration of 
cells of 1.6 x 105 cell/mL per sample. 
Fluorescence time-resolved measurements were made with a Fluorolog Tau-3 Lifetime 
system. Modulation frequencies were acquired between 10 and 250 MHz. Integration time was 
10 s. The fluorescence emission was detected with a 90° scattering geometry. All 
measurements were made using Ludox as a reference standard (τ  0.00 ns). Two independent 
assays were performed for each case. 
3.6.3.  Steady-state anisotropy 
The steady-state fluorescence anisotropy (rss) is based on determining the degree and 
extent of rotational diffusion of the fluorophore (probe) during the lifetime of the excited 
state. Small changes in the stiffness of the matrix surrounding the probe produce changes in 
the rotational movement of the probe and, as such, cause changes in the anisotropy [100]. 
To determine the steady-state anisotropy, the sample is excited with vertically polarized 
light and fluorescence intensities are measured with the emission polarizer oriented parallel 
(III) and perpendicular (I) to the excitation polarizer [100]. 
The steady-state anisotropy (rss) is then defined by the following relationship between the 
relative intensities of fluorescence: 
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                Equation 17 
where G is an instrumental correction factor, given by the ratio of the sensitivities of the 
detection system for vertically and horizontally polarized light [100]: 
||I
I
G                  Equation 18 
The determination of steady-state anisotropy involves the use of probes (extrinsic 
fluorophore) inserted into the membrane, whose photoselective excitation is performed by 
polarizers. If the molecules of fluorophore are present in a highly ordered membrane, as seen 
in the gel or solid-crystalline state or in a viscous solvent, their movement is highly restricted 
and it is induced a parallel orientation of the fluorophore molecules to the vertical excitation 
polarizer. As a result, the molecules of fluorophore emit polarized light because they remain 
immobile during the lifetime of the excited state. However, if the environment surrounding 
the fluorophore is the fluid state, the notorious free rotation of the fluorophore molecules 
pushes a random fluorophore orientation, resulting in a decrease in the emission of polarized 
light. The explanation for this decrease is based on the lack of alignment with the vertical 
excitation polarizer (Figure 13) [100]. 
The application of studies of steady-state anisotropy to membrane models allows the 
determination of the main phase transition temperature of the lipid. The essence of this 
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technique consists on monitoring the anisotropy in a range of temperatures, of a labelled 
suspension of liposomes. 
 
 
 
Figure 13  Effects of polarized excitation and rotational diffusion on the anisotropy of the emission. 
Adapted from [100]. 
Typically, sigmoid curves are obtained which show the variation of the anisotropy of 
fluorophores in liposomes with the temperature, allowing analysing: the influence of the drug 
on the phase transition temperature (Tm) and influence on the anisotropy before and after 
the transition and the transition profile. The parameters of cooperativity (B) and Tm, are 
calculated from the slope and the inflection point of the data fitted to sigmoid curves, 
respectively, using the following Equation 19 [160]: 
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where T is the absolute temperature, Tm is the midpoint of the phase transition, B is a 
measure of the cooperativity of the transition, p1 and p2 correspond to the slopes of the 
straight lines at the beginning and at the end of the plot, and r1 and r2 are the anisotropy 
intercepting values at the y axis. Cooperativity is a concept associated with the transfer of 
energy that is occurring between the molecules at the measured conditions – the higher the 
cooperativity, the more synergistic the energy transfer in the model studied [161]. 
Due to strong packing, the lipid molecules are unable to disorder gradually, and thus, 
when the phase transition occurs, there is a sudden increase in the movements of 
phospholipids. Therefore, the phase transition is a cooperative process where all the lipid 
molecules are involved. The presence of a foreign molecule in the acyl chain region of the 
membrane decreases cooperativity, turning the lipid melting into a more gradual, smooth and 
therefore less cooperative process [162]. It is more frequent that the drugs decrease the 
cooperativity of a process. However, some drugs also increase the cooperativity of the 
transition, from which can be inferred that the drugs are located within the lipid bilayer but 
closer to the polar zone, so its presence does not cause any delay on the lipid melting process 
[163].  
The measurement of fluorescence anisotropy is therefore very useful in evaluating the 
fluidity of the membrane, by providing information about the microviscosity of the lipid 
environment where the probe is inserted and has even applied to assess pathologies and the 
therapeutic action of drugs. For example, fluorescence anisotropy studies have shown that 
patients with active rheumatoid arthritis (pain) have an increased stiffness of the membranes 
of lymphocytes [164]. In turn, using the same technique, it was found that the drugs used for 
the treatment of this disease induce the increase of membrane fluidity of lymphocytes, 
suggesting that the study of changes in membrane fluidity, by means of steady-state 
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anisotropy measurements, can be used to monitor the effectiveness of the treatment of drugs 
[165]. 
In this work, LUVs at a concentration of 500 µM per sample of the defined models labelled 
with either DPH or TMA-DPH were used. The liposome suspensions were incubated without 
drug and with either daunorubicin or doxorubicin at increasing concentrations – 5, 10, 15, 20, 
25, 40 and 75 µM for 30 minutes at 37 ºC and steady-state anisotropy and temperature-
resolved anisotropy was measured for these concentrations. The monitoring of the anisotropy 
was also done for a range of temperatures from 10 to 60ºC for samples with no drug and drug 
at the concentrations of 40 and 75 µM – temperature-resolved anisotropy. The same was 
performed using cell suspensions labelled with the referred probes also at drug 
concentrations of 0, 40 and 75 µM, but the temperature range was 10-50ºC. The cells were 
used at a concentration of 1.6 x 105 cells/mL per sample. Two independent assays were 
performed for each case. 
 
3.7- Statistical Analysis 
Statistical analysis was performed using IBM® SPSS® Statistics software (v.20.0.0.0; IBM, 
Armonk, NY, USA). The measurements were repeated at least twice and data was expressed 
as mean ± standard deviation (SD). Data was statistically analysed through the one-way 
analysis of variance (ANOVA) method and differences between groups were compared by 
Bonferroni and Tukey post-hoc tests in which a p value lower than 0.05 (p0.05) was 
considered statistically significant. 
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Chapter 4  
Results and Discussion 
4.1- Liposome Characterization 
The formulations designed were characterized as explained above, to guarantee they 
possessed the characteristics of interest for the following studies. Particle size was measured 
through DLS and is presented in figure 14. 
  
Figure 14 Size distribution of liposomes in the four fourmulations designed (normal, normal with 
cholesterol, tumoral, and tumoral with cholesterol) with increasing concentrations of daunorubicin 
and doxorubicin ranging from 0 to 75 µM. * represents that means are significantly different (p<0.05) 
relatively to the suspensions without drug (0 µM) of the same model. 
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From figure 14 it is possible to verify that the liposomes produced were in fact 100 nm in 
diameter as desired. Even though some statistically significant differences can be seen for 
the normal with cholesterol model, overall the addition of the drugs does not appear to 
produce substantial effects in the size of the liposome formulations studied. 
As described previously in this document, normal cell membranes are composed of a 
number of molecules charged differently, but these are present at certain equilibrium so that 
the surface charge is close to 0 as described in the literature [54, 56]. Contrarily, tumor cell 
membranes expose to the outer leaflet of the membrane anionic lipids such as PS, having 
therefore a negative surface charge [54, 56]. The determination of the zeta potential of the 
designed mimetic membrane models helps comprehend if these changes can also be 
mimicked. 
Figure 15 represents the zeta potential for the four models prepared without any drug 
and with 3 concentrations of either daunorubicin or doxorubicin – 5, 40 and 75 µM. First, 
these values will be used to assess the similarities of the models to actual cell membranes. 
Secondly, the effect of each drug and the referent concentrations on the surface charge of 
the models will be explored, and finally, an overall review of the meaning of the zeta 
potential values obtained will be done. 
 It can be observed that for the normal formulations with or without cholesterol, the zeta 
potential values are around 0, which indicates neutral surface charge, while for the tumoral 
formulations negative values of zeta potential were obtained. This is consistent with what is 
found in actual cell membranes (normal and tumoral, respectively), and as such we can 
conclude that the proposed formulations successfully mimic the surface charge of the cell 
membranes they’re intended to be models for. 
A tendency can be observed for the tumoral models as it appears that the zeta potential 
becomes less negative and tends towards neutrality as the drug concentration is increased. 
That is likely to happen because both drugs (pKa=8.4)[95] are positively charged at the pH 
values used during the assays due to their amine group (see figure 8). This might mean that 
Figure 15 Zeta potential of liposomes in the four formulations designed (normal, normal with 
cholesterol, tumoral, and tumoral with cholesterol) in increasing concentrations of daunorubicin and 
doxorubicin ranging from 0 to 75 µM. * represents that means are significantly different (p<0.05) 
relatively to the suspensions without drug (0 µM) of the same model. 
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the positively charged amine group is able to interact with the negatively charged phosphate 
groups at the polar heads of the anionic phospholipids (especially due to the increase in the 
amount of PS on the outer leaflet of the membrane), neutralizing those charges via these 
interactions. 
In general, liposome formulation characterization allowed to confirm that the membrane 
models were prepared as intended, with surface charge that is similar to that of normal and 
tumoral cells and a diameter that creates a membrane curvature similar to that of actual 
cells. 
Although it can’t be said without doubt that interactions between the two drugs and the 
four models are occurring, the results give some indications that that might be happening. To 
confirm and help understand these interactions, further studies were performed. 
 
4.2- Membrane Partition Studies  
 
The membrane partition, analysed by the measure of the partition coefficient (Kp), was 
performed through derivative spectrophotometry. As explained in the chapter 3, lipid 
suspensions were prepared at a range of lipid concentrations from 100 to 1000 µM – these 
were the reference samples. Similar ones were prepared with drug at a fixed concentration 
of 40 µM. 40 µM solutions of only drug in buffer were also prepared. All of these were placed 
in 96-well plates and the absorbance spectra were measured. Studies were performed 3 times 
independently. Once confirmed that the values of all three replicas were coincident, the 
mean values of the samples, references and drug spectra were introduced in a Microsoft 
Excel® application created by Doctor Cláudia Nunes – Kp Calculator [150]. The mentioned 
absorbance spectra obtained are represented as an example in figure 16. 
 
 
Figure 16 Absorbance spectra plotted from the experimental data. In this case it is shown the data 
plotted from the normal model for the drug daunorubicin. 
The absorbance spectra values from the reference samples were subtracted to the values 
referent to the samples containing drug. From this data, and to decrease the noise associated 
with the microscattering as previously explained, the first, second and third derivative were 
calculated, being an example of the third derivative represented in figure 17. The third 
derivative is usually chosen for the following steps since it allows for a better reduction of 
the noise caused by the microscattering associated with the liposomes. From the spectrum of 
the third derivative, four peaks are chosen and the values for each drug concentration at the 
four wavelengths chosen are collected, as is represented for one wavelength in figure 17. 
These values were then inserted into the Origin Pro 8.5.1 software, plotted and a non-linear 
curve fitting was calculated using Equation 4, described in Chapter 3 of this document. The 
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resulting plot of the derivative data and the fitting associated are also represented in figure 
17. 
From this fitting it is possible to obtain the Kp value for each wavelength tested, being 
the final Kp the average of these values for that drug using that mimetic model. To obtain 
adimensional Kp values and remove the influence of the different microenvironments of the 
different models, the values obtained before are divided by the specific molar volume of the 
lipids used in that specific mimetic model. 
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Figure 17 Third derivative spectrum of the data from figure 16 and the respective actual data for a 
particular wavelength (above). Below is the fitting performed using the Origin Pro software.  
The adimensional Kp values found for both daunorubicin and doxorubicin using the four 
mimetic models are represented in figure 18. These allow the analysis of 3 main factors. First 
the two drugs will be compared; then, the effect of cholesterol in the membrane models will 
be evaluated; finally, a comparison of normal vs. tumoral models can be made. 
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Regarding the two compounds tested, it is very clear that they partition very differently 
into the different membrane models. In the normal model, the drug doxorubicin partitions 
into the membrane approximately 12 times more than daunorubicin does. In the case of the 
normal model containing cholesterol, the same tendency applies, with doxorubicin 
partitioning 38 times more than daunorubicin. Since the only difference between the two 
drugs is that doxorubicin has an alcohol group, the results indicate that this alcohol group is 
likely to be involved in the higher partition of the drug into the normal membrane models. A 
hypothesis that can be formulated is that, besides the interaction of the drugs’ amine group 
with the membrane, this OH group might be establishing hydrogen bonds with the ester 
groups of the phospholipids. In the case of the normal model with cholesterol, this partition 
decreases, once the model becomes more rigid it does not have as many ester groups 
available do establish the hydrogen bonds. This is not observed for the tumoral models. Both 
drugs partition similarly into the membranes of the tumoral model. However, for the tumoral 
model with cholesterol, doxorubicin partitions slightly less into the membrane than 
daunorubicin. 
From the results obtained it appears that the presence of cholesterol has a particular 
effect in the different model membranes. In the normal models, drug partition is lower when 
cholesterol is present in the membrane, which was to be expected since it is known that in 
nature cholesterol generally makes the membrane more rigid and more compact. In the case 
of daunorubicin, there is very little partition into the normal with cholesterol membrane, 
being this value by far significantly the lowest of all. However, in the tumoral models, the 
drugs partition more when cholesterol is present. A possible explanation for this resides in 
the fact that cholesterol creates microdomains such as lipid rafts by associating with other 
components of the membrane such as the PS. These are localised structures that are rigid and 
Figure 18 Partition Coefficient (Kp) values for both drugs used in the sudy, daunorubicin and 
doxorubicin, determined though derivative spectrophotometry using four different lipidic mimetic 
models of the membrane – normal, normal with cholesterol, tumoral and tumoral with cholesterol.* 
represents significant difference (p<0.05), comparing the models for the same drug. 
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overall tend to decrease the fluidity of the membrane. It might be the case that cholesterol 
is forming these microdomains in the tumoral mimetic model that contains cholesterol, and 
that the remaining lipids of the membrane outside of these microdomains are becoming more 
permeable due to the absence of cholesterol there to compact, and as a result the 
cholesterol is improving drug partition in the case of the tumoral membrane models. It is also 
interesting to notice that in the literature, lower amounts of anionic phospholipids in the 
membrane were seen to cause an increase in their permeability for both anthracyclines [95, 
108]. Therefore it may be fair to conclude that the decreased proportion of PS, an anionic 
lipid, in the membrane of the tumoral with cholesterol is favorable for the uptake of both 
drugs, which might be related to the possibility that PS is one of the main lipids to form 
complexes or domains with cholesterol. 
Finally, comparing the models taking into account the type of tissue they try to mimic, 
it’s clear that daunorubicin partitions much better into the tumoral model containing 
cholesterol, which is a factor of much value to its therapeutic effect especially since it seems 
that the drug has higher affinity towards tumoral models. Doxorubicin, while partitioning less 
into the tumoral membranes than into the normal ones, still has very high partition 
coefficients in the case of the tumoral models, which also plays in favor of its effectiveness in 
treatment. These findings are in accordance to the literature, which suggests that membrane 
models of higher heterogeneity (mixtures of lipids) usually promote the interaction, partition 
or even penetration of drugs such as doxorubicin into the the membranes [87-89]. 
Overall, it can be concluded that, with the exception of daunorubicin in the normal with 
cholesterol model, the drugs partition very well into all the membranes of the tested models, 
which could explain why they are to this day some of the most used for chemotherapy but 
also why they have such severe side effects - since the high partition is also verified for the 
normal cell-mimicking models, there is high cytotoxicity not only for the tumoral cells, but 
also to the normal ones.  
 
Table 6 Logarithmic values of the partition Coefficient (Kp) values for both drugs used in the 
sudy, daunorubicin and doxorubicin, determined though derivative spectrophotometry using 
four different lipidic mimetic models of the membrane – normal, normal with cholesterol, 
tumoral and tumoral with cholesterol, as well as the partition coefficient for each drug found 
via the octanol/water method. 
  
In fact, while doxorubicin causes the same kind of side effects as daunorubicin, the 
effects associated with the first are much more severe, being doxorubicin considered a more 
aggressive drug [119-121]. The findings described are consistent with that, showing a 
partition of doxorubicin into normal membranes that is several times higher than that of 
daunorubicin and than that of doxorubicin in tumoral models.     
The results obtained using the method of derivative spectrophotometry were then 
compared to the values of partition for both drugs described in the literature determined 
 
Octanol/Water 
Method  
Derivative Spectrophotometry [log(Kp)] 
 
Log(P) [166] Normal 
Normal with 
Cholesterol 
Tumoral 
Tumoral with 
Cholesterol 
Daunorubicin 1.83 3.27 ± 0.05 2.49  ± 0.04 3.28 ± 0.04 3.55 ± 0.03 
Doxorubicin 1.27 4.34 ± 0.01 4.07 ± 0.07 3.30 ± 0.01 3.44 ± 0.04 
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through the octanol/water partition method. Since these values are usually presented, from a 
pharmaceutical point of view, in the logarithmic form, table 6 presents the partition 
coefficient of both drugs in logarithmic form using both methods. 
As mentioned before, octanol, the organic phase of the octanol/water method, lacks the 
amphiphilic nature that is so characteristic of phospholipids and essential for the cell 
membranes’ structure [131-134]. As such, this method bears very little resemblance to the 
actual biomembranes found in nature. On the other hand, using liposomes as model 
membranes solves this problem as these are very similar to biomembranes. In table 6 it is 
shown that the partition coefficient values found in this study using derivative 
spectrophotometry are very different from those found using the octanol/water method. The 
Kp values found in this study are actually much higher than those of the octanol/water 
method. This proves that the interactions between the two drugs and the membranes involve 
not only hydrophobic but also electrostatic and Van der Waals interactions as well as 
hydrogen bonds, which are facts supported by previous research [95, 108]. Thus, the 
liposomes/water system appears to be a much more effective, complete and accurate way of 
determining the partition coefficient and therefore obtaining information regarding the way 
the drugs partition into the biomembranes. The transition in industry and research of the use 
of the octanol/water method to the use of model membranes to determine partition 
coefficient could in the future prove to be a great improvement in both fields. 
 
 
4.3- Membrane Location of Daunorubicin 
 
Membrane location assays were performed for the drug daunorubicin using the four 
models designed for this study. The same assays were performed for a line of tumoral cells, 
the line MDA-MB-231 that can be seen in figure 19, in order to produce results that could be 
comparable to those of the models. The assays were performed using liposomes and cells 
labeled with either DPH or TMA-DPH. These are two fluorescent probes that have a known 
and described location in the membrane. Since their location in the membrane is known, the 
proximity of the drug to these probes can give information on their own location in the 
membrane. That is because the probes’ fluorescence is deactivated by the proximity of the 
drug, a phenomenon called quenching.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 MDA-MB-231 cells cultured with RPMI U1 25mM Hepes and 5% FBS observed after 2 days of 
growth under an inverse microscope at a magnification of 1000x. 
 Assessment of Anticancer Drugs’ Effects on Membrane Biophysical Properties using Model Membranes 
 
60 
 
As explained in Chapter 3, there are two types of mechanisms for fluorescence 
quenching: static and dynamic or collisional quenching. When quenching is static, a 
permanent complex is formed between the fluorophore and the quencher and the lifetime 
measurements remain constant for each sample, which would mean that the KD would equal 
zero. The dynamic or collisional mechanism involves the interaction of the quencher with the 
fluorophore in the excited state, but this is temporary since the fluorophore then returns to 
ground state. If this is the mechanism, the I0/I values would form a linear plot, that should 
be superimposable with τ0/τ, meaning that KSV is equal to KD. Since neither case is observed, 
it is fair to infer that the mechanism of quenching involves combined static and dynamic 
quenching. 
The chosen fluorescent probes to be used in this study were DPH and TMA-DPH. These are 
interesting because they insert into the lipid bilayer, possessing however an important 
distinction. The DPH probe possesses a structure that is hydrophobic (represented in figure 
20) and as such inserts into the acyl chain region of the phospholipidic membranes, being 
therefore more internally located. The TMA-DPH (figure 20) is very similar to DPH, however it 
contains an amine group which is polar and therefore able to interact with the polar heads of 
the phospholipids. DPH will tend to be nearest to the center of the bilayer due to its affinity 
to the fatty acid tails of the phospholipids. TMA-DPH, although being partially inserted 
between the acyl chains, also interacts with the polar regions, therefore locating at a sort of 
transition region between the polar and apolar zones of the phospholipids, allowing the 
acquisition of information at a more superficial level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The closest the drug’s proximity, the more the deactivation of the probe’s natural 
fluorescence. With that information, correlations can be made using an array of samples of 
increasing drug concentrations to in turn determine biophysical parameters that can help 
shine light on the drug location. The determination of the drug-induced quenching involves 
the measurement of the fluorescence emission spectra of samples at a lipid concentration of 
500 µM and drug concentrations from 0 to 75 µM. These spectra can be obtained through a 
regular spectrofluorimeter, in which each sample has to be changed manually, or by a plate 
Figure 20 Schematic representation of the structure of the fluorescent probes DPH and TMA-DPH and 
their average location next to an example of phospholipid (to the right of each probe), which is the 
constituent of a lipid bilayer. This image was kindly provided by MSc Ana Catarina Alves. 
Center of the Bilayer 
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reading spectrofluorimeter, in which all samples are introduced in a 96-well plate and all the 
samples are inside the equipment throughout the whole reading process. Now, a regular 
spectrofluorimeter has the advantage of a higher sensitivity. However, since it can only hold 
one sample at a time and these have to be manually changed, it is a much more morose and 
time-consuming process to use this device. Also, in cases such as this when it is very 
important to keep the samples in the dark to avoid fluorescence bleaching and always at 37ºC 
to ensure the measurements are done at that specific temperature, this method involves 
some sample disturbance by having to transport them at room temperature from the 
incubator to the device and having to open the sample holder sometimes to measure the 
temperature, which might impair both needs. On the other hand there is the plate reader, 
which is a slightly less sensitive equipment. However, it has the advantage of allowing the 
introduction of all the samples at the same time, which reduces light and room temperature 
exposure. Also, it can be programmed to incubate the samples at the desired temperature for 
a certain time, ensuring that the spectra readings are done at that temperature. In this case, 
the plates were incubated for 10 minutes at 37ºC prior to reading. The measurements are 
also programmed once the plate is inserted, which makes the process much more expeditious 
since the operator does not need to be present during the measurements. 
The plate reading spectrofluorimeter seems to be a more practical and advantageous 
alternative, but its use needed to be validated to ensure that this methodology works in this 
apparatus once there is no described protocol. For that purpose, the fluorescence spectra 
(emission and excitation) measurements were performed in both devices. The results for both 
equipments can be seen in Annex I. 
The dynamic constant (KD) remains the same since the measurements for its 
determination were performed in a different fluorimeter (one able to perform lifetime 
measurements). The comparison must therefore be done between mainly the static constants 
represented (KS), which were obtained directly from the slopes of fitting curves obtained 
using equation 11 on the emission  spectra maximum values. Since KD values are the same and 
the Stern-Volmer constant, KSV, is a calculated as KS+KD, this constant can also be used to 
compare the two devices used. 
Overall, it can be observed that the values of KD and KSV obtained using the two devices 
were quite similar, and, as such, the use of the plate reader on its own is a valid choice. 
Small differences in the values between devices are easily explained by the vast array of 
disturbing conditions the samples suffer in the regular spectrofluorimeter measurements, 
such as more light incidence and temperature variations, even with the utmost care from the 
operator. The results for the regular spectrofluorimeter present very small values of standard 
deviation, while in general the results obtained with the plate reader have wider standard 
deviation values, which is according to the fact that the latter has a lower detection limit, 
allowing for less precise measurements. In the end, we conclude that although the regular 
fluorimeter is more precise, both of the devices are very accurate and can be used for these 
procedures. 
To make easier the visualization and understanding of the results, only the results 
obtained using the plate reading spectrofluorimeter will be shown in figure 21. 
The Stern-Volmer quenching constant (KSV) indicates the sensitivity of the fluorophore to 
a quencher. Higher values of the Stern-Volmer constant mean higher deactivation (quenching) 
of the fluorophore. The bimolecular quenching constant, or Kq, represented in figure 22, is 
often used to reflect the efficiency of quenching or the accessibility of the fluophores to the 
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quencher. Kq eliminates the contribution of the intrinsic lifetime of the probe and therefore, 
when comparing different probes with different lifetimes, Kq represents a much more 
accurate parameter. In this sense, all the comparisons beneath will take that constant into 
account. 
 
 
Figure 21 Plotted results of the static, dynamic and Stern-Volmer constants determined using a a plate 
reading spectrofluorimeter. These constants were determined for all four models plus the tumoral cells 
MDA-MB-231, under the effect of daunorubicin, for the two probes, DPH and TMA-DPH. 
In figure 22 it is evident that for the normal and tumoral model without cholesterol drug 
locates closer to the location site of TMA-DPH, while for both models with cholesterol the Kq 
value is close between the two probes.  
This leads to conclude that, for the models without cholesterol, daunorubicin is located 
at a more superficial zone, having its amine group interacting with the phosphate groups of 
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Figure 22 Bimolecular quenching constant (Kq) determined using a a plate reading spectrofluorimeter. 
These constants were determined for all four models plus the tumoral cells MDA-MB-231, under the 
effect of daunorubicin, for the two probes, DPH and TMA-DPH. 
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the polar heads of the phospholipids while the rest of the drug molecule inserts in between 
the acyl chains of the lipids. 
In the case of the models with cholesterol, it is possible that cholesterol, having a small 
headgroup with affinity to choline, may prevent the interaction of the amino group of 
daunorubicin with the phosphate group due to steric hindrance. Therefore the quenching 
effect is less noticeable at the TMA-DPH region when comparing with the model without 
cholesterol. Nevertheless and comparing with all the other lipid models, the normal model 
containing cholesterol resulted in very low values for all the constants. This means that very 
little drug could be found nearing either location of the probes. This is consistent with the 
very low partition coefficient obtained for daunorubicin – if the drug isn’t able to partition 
into the membrane or partitions very little, then there’s very little drug to interact with the 
fluorophores and the resulting constant values are very low. 
For the tumoral cells, the obtained Kq values also point to a drug location closer to TMA-
DPH. However, the constant values found for DPH using the tumoral cells were much lower 
than those of the tumoral model, which makes sense considering the much higher complexity 
of a biomembrane, containing a wide variety of different domains and molecules in large 
quantities that might prevent the drug from penetrating it with ease. 
 
4.4- Membrane Fluidity 
4.4.1.Temperature-Resolved Anisotropy 
When measuring anisotropy along a range of temperatures, an anisotropy profile is 
obtained such as is shown in figure 23 as an example. 
At lower temperatures, a plateau of high anisotropic values exists, which represents the 
solid-crystalline or gel phase of the lipids (Lβ). The temperature at which the arrangement of 
the lipids shifts to form a fluid or liquid-cristaline phase (Lα) is known as the phase transition 
temperature or Tm. 
Revealing information can be gathered from both observing the obtained anisotropy 
profiles for each sample and calculating the phase transition temperature. Since we 
Figure 23 Anisotropy profile from 10 to 60ºC to the normal model with no drug for the probe DPH. The 
gel phase and liquid-crystalline phases are represented as Lβ and Lα, respectively. The phase transition 
temperature or Tm is the inflexion point of the plot. 
Lβ 
Lα 
Tm 
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performed the phase transition temperature measurements for liposome suspensions without 
drug and with two concentrations of drug (daunorubicin and doxorubicin) for the two 
fluorescent probes, it is possible to determine if the drugs are causing higher fluidity of the 
membranes, the phase they are causing differences on and the membrane location where 
those changes are happening as well. 
However, it is also interesting to know the differences in fluidity for the different models 
without the involvement of the drugs, mainly because it can allow a comparison with the 
fluidity of biomembranes in nature. Figure 24 represents the profiles for the liposome 
suspensions of each model for both probes. 
 
 
  
 
 
 
 
 
 
 
 
 
From figure 24 it is clear that the models have very different behaviors in terms of 
fluidity in the range of temperature used. Moreover, different profiles depending on the used 
probe are obtained. As the TMA-DPH reports to a zone closer to the polar head groups it 
represents higher anisotropy values when compared with the profile obtained for DPH. 
For DPH, the normal model shows the highest rigidity in the gel phase but one of the 
lowest in the fluid phase, which means that in the gel phase the normal model is the most 
rigid but that does not happen after the phase transition. It is also possible to see, in the acyl 
chains region, a stabilizing effect of cholesterol, for both models with cholesterol, fluidizing 
the gel phase and stiffening the fluid phase. In what concerns the head group region, 
cholesterol has a stiffening effect due to its electrostatic interaction with the choline group. 
Moreover, and due to the increment of serine in the tumoral model, which has a bulky head 
group, the tumoral mimetic model is more rigid in this region contrarily to the very simple 
normal model. 
It is also worth pointing out that in both regions the probes report to, the tumoral models 
tend to be more fluid overall and particularly near the 37ºC temperature than the normal 
with cholesterol model, which in reality is the one with physiological interest since normal 
biomembranes are never made of only one lipid (like is the case of the normal model). This is 
in accordance with what was intended, and as such it is proof that these models were indeed 
able to mimic the higher fluidity of tumoral cell membranes. 
Figure 25 gathers the anisotropy profiles of the four models labeled with two probes 
without drug and for two drug concentrations (40 and 75 µM).  
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Figure 24 Anisotropy profiles for the four different liposome models membranes labelled with both of 
the fluorescent probes used (DPH and TMA-DPH).  
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Figure 25 Anisotropy profiles for the four different liposome models designed labelled with both of the fluorescent probes used (DPH and TMA-DPH). For each model and each 
probe a sample with no drug and two other at drug concentrations of 40 and 75 µM were prepared and the profiles obtained are shown in this figure. This figure shows profiles 
where the drug used was daunorubicin. 
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In general, the normal model with cholesterol appears to be unchanged with the addition 
of drug for both probes. If we look back to the partition coefficients obtained for the model 
normal with cholesterol, these were very small for daunorubicin, which is consistent with the 
lack of alteration in fluidity. 
For the tumoral models, at physiological temperature, the presence of daunorubicin 
seems to result in an increase in membrane rigidity at least at a more internal level of the 
bilayer, as seen in the profile obtained using DPH. The more interfacial or superficial zone of 
the membrane (given by TMA-DPH) seems to suffer no alterations. However, the tumoral 
model containing cholesterol appears to become more fluid in the same conditions in both 
regions, which is consistent with the fact that both drugs partition more into this model than 
the one without cholesterol. This observation supports the hypothesis that cholesterol, by 
bonding with the polar heads of certain lipids, creates microdomains that are rigid, but might 
be localized and leave the rest of the surface area more fluid. This is consistent with the 
values of Kp, which are higher for both drugs for the tumoral model that contains cholesterol. 
 
Table 7 Phase transition temperatures (Tm) and Cooperativity values for the four models and 
the two probes (DPH and TMA-DPH) without daunorubicin and at daunorubicin concentrations 
of 40 and 75 µM. 
  
Tm (ºC) Cooperativity 
  
Drug Concentration Drug Concentration 
Model Probe 0 µM 40 µM 75 µM 0 µM 40 µM 75 µM 
Normal 
DPH 27.3 ± 0.7 27 ± 1 27.1 ± 0.8 166 ± 12 148 ± 12 150 ± 24 
TMA-DPH 25.14 ± 0.09 25.7 ± 0.1 25.6 ± 0.7 213 ± 11 168 ± 37 145.2 ± 0.6 
Normal with 
Cholesterol 
DPH 40 ± 3 39.6 ± 0.6 40 ± 0 62.2 ± 0.1 71 ± 8 69.52 ± 0.01 
TMA-DPH 38 ± 3 36 ± 2 40 ± 0 57 ± 5 70 ± 5 55 ± 5 
Tumoral 
DPH 29.00 ± 0.02 29 ± 1 29.2 ± 0.4 95 ± 10 168 ± 34 209 ± 10 
TMA-DPH 28.8 ± 0.9 29.1 ± 0.5 30 ± 1 
111.5 ± 
0.4 
97 ± 36 156 ± 15 
Tumoral 
with 
Cholesterol 
DPH 35.0 ± 0.5 32 ± 1 30.88 ± 0.08 76 ± 8 122 ± 32 137 ± 12 
TMA-DPH 33.36 ± 0.06 31.44 ± 0.02 32 ± 1 70 ± 6 93 ± 12 97 ± 13 
 
More information can be gathered from observing the phase transition temperature (Tm) 
and cooperativity values of the membrane models labeled with the two probes at these three 
concentrations of daunorubicin. This information can be seen in table 7. 
The only clear tendency regarding the Tm is that it decreases for the tumoral with 
cholesterol model with the DPH probe, which means that the membrane becomes more fluid. 
The same appears to happen with the probe TMA-DPH. For the remaining models no tendency 
can be observed. That might be better explained by associating again with the results 
obtained for the membrane partition. Daunorubicin partitions the most into the membrane of 
the tumoral with cholesterol model, and that would make it so that this drug is more able to 
interact with the fluorescent probes in this model than in the other ones, justifying the 
aforementioned findings. 
Regarding cooperativity, the cooperative zone is usually associated with the first segment 
of the acyl chains bound to the polar head of a phospholipid, commonly the C1-C8 region 
[110]. In this sense, daunorubicin appears to be located the interfacial region,since the 
cooperativity in this model increases with the increase in concentration of drug, and the 
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increase in cooperativity values is associated with an interaction with the polar heads [167]. 
Since the drug has a positively charged amine group at the pH values used in the study, these 
interactions with the polar heads are most likely between this amine group and the 
negatively charged phosphate groups of phospholipids. 
The normal with cholesterol model is the one with which daunorubicin partitions the 
least, which is consistent with the lack of alteration in Tm and the very low values of 
cooperativity. 
In the case of the models without cholesterol, it is shown that, although they partition 
similarly, the cooperativity values decrease in the case of the normal model but increase in 
the tumoral model. That might occur because the tumoral model is much more 
heterogeneous, and, since the drug is a small molecule, it can function the way that 
cholesterol does for the models containing cholesterol and organize the membrane lipids. In 
fact, phosphatidylserine, one of the lipids in the tumoral model membrane, possesses a very 
large polar head, that can favour the packing of a smaller molecule like daunorubicin. In a 
membrane as heterogeneous as the one from the tumoral model, the energy transmission is 
very heterogeneous as well. However, if the packing increases in the membrane as an effect 
of daunorubicin as theorized above, the energy transfer can become more homogeneous, 
which could explain the increase of cooperativity. The normal model is already very 
homogeneous since it is composed of only one lipid type. As such, any interference, like the 
inclusion of daunorubicin into the membrane, hinders the energy transfer, hence leading to 
the decrease in cooperativity. 
The tumoral model becomes more rigid, which can be observed by the anisotropy profile 
for this model with DPH as well as by the increase in cooperativity. This doesn’t seem to 
happen in the tumoral with cholesterol model. This could be explained by the possibility that 
daunorubicin, as explained above, may be associating with other constituents of the tumoral 
model membrane that make the membrane more rigid, while it can be making the tumoral 
with cholesterol membrane more fluid by disorganizing the membrane structure in this 
model, leading to the decrease in Tm.  
The temperature-resolved anisotropy was also measured with the tumoral cells to assess 
the effect of daunorubicin, but the results produced did not make possible the acquisition of 
phase transition temperatures or cooperativity values. However, from the anisotropy profiles, 
depicted in figure 26, some inferences can be made. For example, it is noticeable that in the 
absence of drug, the polar region of the cell membrane bilayer is more rigid than the 
hydrophobic center. Curiously, the addition of daunorubicin seems to cause the polar regions 
of the membrane to become more fluid, while the hydrophobic chains become slightly more 
rigid. The biggest alterations in profile are found for the probe TMA-DPH, which indicates 
that also in the cell membrane of tumor cells the drug appears to locate in the cooperative 
zone, inserting in the acyl chains but also interacting with the polar heads. The observations 
for the tumoral cell anisotropy profiles are in fact similar to those made for the liposome 
tumoral with cholesterol model. This is more evidence that the models designed are in fact in 
the right path towards the validation of models for biophysical membrane studies. 
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Temperature-resolved anisotropy measurements were also performed for a range of 
temperatures from 10 to 60ºC using the same models and probes but testing the drug 
doxorubicin. The anisotropy profiles of the four models labeled with two probes without drug 
and for two drug concentrations (40 and 75 µM) of doxorubicin are shown in figure 27. 
Overall, the profiles found for doxorubicin are very similar to those found using the other 
drug tested, daunorubicin. As such, the same observations made for daunorubicin regarding 
fluidity by analysis of the anisotropy profile can be applied to the case of doxorubicin. 
The phase transition temperature, Tm, and cooperativity were also determined for 
doxorubicin and are established in table 8. 
 
Table 8 Phase transition temperatures (Tm) and Cooperativity values for the four models and 
the two probes (DPH and TMA-DPH) without doxorubicin and at doxorubicin concentrations of 
40 and 75 µM. 
  Tm (ºC) Cooperativity 
  Drug Concentration Drug Concentration 
Model Probe 0 µM 40 µM 75 µM 0 µM 40 µM 75 µM 
Normal DPH 26.83 ± 0.09 27.6 ± 0.1 27.80 ± 0.02 115 ± 2 127 ± 2 121 ± 12 
TMA-DPH 25.21 ± 0.01 25.7 ± 0.2 25.7 ± 0.9 198 ± 33 167 ± 40 139 ± 21 
Normal with 
Cholesterol 
DPH 39 ± 1 40.5 ± 0.6 38 ± 3 66 ± 10 62 ± 3 70 ± 12 
TMA-DPH 40.001 ± 0.002 40.000 ± 0.003 40.007 ± 0.008 67 ± 4 53 ± 5 71 ± 21 
Tumoral DPH 29 ± 0.8 30 ± 1 30.5 ± 0.8 89 ± 15 110 ± 20 118 ± 28 
TMA-DPH 29.1 ± 0.4 29.3 ± 0.8 31.2 ± 0.4 118 ± 5 111 ± 16 168 ± 31 
Tumoral with 
Cholesterol 
DPH 33 ± 0 31 ± 2 31 ± 1 87 ± 0 83 ± 25 94 ± 12 
TMA-DPH 33.34 ± 0.05 31.39 ± 0.08 32 ± 1 70 ± 6 91 ± 14 85 ± 3 
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Figure 26 Anisotropy profiles for the tumoral cell line MDA-MB-231 labelled with both of the fluorescent 
probes used (DPH and TMA-DPH). Anisotropy was measured for samples with no drug, and at two 
concentrations of drug, 40 and 75 µM. 
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Figure 27 Anisotropy profiles for the four different liposome models designed labelled with both of the fluorescent probes used (DPH and TMA-DPH). For each model and each 
probe a sample with no drug and two other at drug concentrations of 40 and 75 µM were prepared and the profiles obtained are shown in this figure. This figure shows profiles 
where the drug used was doxorubicin. 
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However, as opposed to what occurs in relation to daunorubicin, doxorubicin does not 
seem to produce any tendency towards Tm alteration in any of the membrane models, but 
some similarities in the tendencies of the cooperativity values can be seen. A tendency 
towards a decrease in cooperativity can be observed using the probe TMA-DPH for the normal 
model, which means that the energy transfer at the polar head region of the bilayer in being 
impaired with the addition of doxorubicin. As such, an explanation might be that the normal 
bilayer, made up of only one type of lipid, is very homogeneous, and therefore in normal 
conditions, energy transfer happens smoothly and homogeneously. When an exogenous factor 
is introduced, in this case, the doxorubicin drug molecule, the homogeneity is impaired, and 
the energy transfer as a result is as well, resulting in a decrease in cooperativity. This means 
that the molecules can be located near the phospholipid headgroup, then moving away. In 
the case of the tumoral model, the opposed tendency happens, so the cooperativity 
increases. This might be again because the tumoral model membrane is already 
heterogeneous, and in such a case, the doxorubicin molecule might actually come to have a 
stabilizing effect, with its amine group interacting with the phosphate groups from the polar 
heads of the phospholipids and the remaining of the molecule interacting via hydrogen bonds 
or Van der Waals forces with the cooperative zone. A more stable structure facilitates the 
passage of energy, which explains the increase in cooperativity for this model with the 
increase in doxorubicin concentration. 
 
4.4.2. Steady-State Anisotropy 
 
Steady-state anisotropy was also measured using liposomes of the four models labeled 
with either DPH or TMA-DPH to assess the effect of increasing concentration of daunorubicin 
at 37ºC. The results of such measurements are represented in figure 28. 
Using the probe DPH, it can be seen that the normal with cholesterol membrane model 
suffers no alterations in fluidity at the physiological temperature, which is consistent with all 
the previous data. The normal and tumoral models seem to become slightly more rigid at the 
hydrophobic area at concentrations of drug up to 20 µM. This is in agreement with the 
findings through temperature-resolved anisotropy. Interestingly, above that concentration of 
drug, this effect stagnates, which seems to suggest that a saturation level is achieved, and 
that these models can only incorporate the drug up to a certain concentration, which would 
be, as mentioned, approximately 20 µM. It could perhaps be useful to try to perform 
temperature-resolved anisotropy measurements for these (or all) models again but using drug 
concentrations below 20 µM. In that situation, the measurements would be performed in 
conditions where the drug was still being incorporated and not after the membrane was 
saturated, which could allow the determination of more distinct profiles with more accurate 
phase transition temperatures and cooperativity values. 
As for the tumoral with cholesterol model, it does not suffer alterations until higher 
concentrations of drug are achieved (40 and 75 µM), at which point the membrane becomes 
more fluid. The same seems to happen to tumoral cells, which presents another biophysical 
similarity between the models designed and the cells they were designed after. 
When focusing on the more superficial area of the bilayer by attending to the anisotropy 
at 37ºC obtained for TMA-DPH-labeled cells, one can once again verify no changes in fluidity 
associated with the normal with cholesterol model. Unexpected, however, could be the fact 
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that no changes can be seen for the tumoral with cholesterol model either, which is very 
different than what is found for tumoral cells, whose membrane appears to become more 
fluid also at the polar regions. However, one must keep in mind that these are still very 
simple models compared to cells, which usually possess a variety of proteins, ions and 
molecules anchored to its surface, something that was not mimicked in this study. As for the 
normal and tumoral models, no alterations can be seen unless at higher concentrations of 
drug (40 and 75µM), at which the membrane becomes slightly more fluid. 
As such, it can be concluded that the drug daunorubicin appears to have a packing effect 
on the hydrophobic region of the phospholipids, probably at the cooperative zone, for the 
models without cholesterol, while making the membrane of the tumoral with cholesterol 
model more fluid at that region, being consistent with the findings for tumoral cells. 
Summarily, this is in accord with the idea that the drug probably is located in the 
cooperative zone while also interacting with the polar heads of phospholipids. Furthermore, 
it confirms some more similarities between the models of this study and the membranes of 
tumoral cells, which proves this study to be a great and crucial step towards the validation 
and standardized use of liposomes as model membranes in biophysical studies. 
 
 
4.5- Cell Viability 
 
To ensure that the probes and drug used did not induce a level of cytotoxicity that could 
jeopardize the results, cell viability was confirmed by counting the live cells via the Trypan 
Blue Exclusion method before and after incubation with the compounds. Although this assay 
is not a valid choice when viability is in fact the key parameter in study, since the intention 
was only to confirm that there was a high percentage of live cells even after the assays were 
finished, a simple counting method such as this was employed. 
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Figure 28 Steady-state anisotropy values found using DPH and TMA-DPH fluorescent probes on for the four 
membrane models and the tumoral cells MDA-MB-231 with no drug or under the effect of daunorubicin. 
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Figure 29 shows the percentage of cells before and after the addition and incubation for 1 
hour with the used probes. 
 
 
Figure 29 Percentage of cells counted before and after the incubation of the cells for 1 hour with the 
probes. 
The number of cells counted before the addition of any probe was normalized to 
correspond to 100%. The results show that the both of the probes appear to be innocuous, 
since the percentage of cells after incubations remains approximately the same. As such, the 
methodologies could proceed. 
Since the drugs used are cytotoxic, the assays were performed by keeping the time of 
contact between the cells and the drugs to a minimum. To ensure that the measurements 
were correctly performed, cells were counted once again after the different methods were 
employed and the results are presented in figure 30. 
 
 
Figure 30 Percentage of cells counted after the employed methodologies. The number of cells counted 
for the suspension without drug (0 µM) was normalized to represent 100%. The samples containing 20 µM 
and 40 µM of daunorubicin (for both probes) were chosen and the cells in them counted to ensure 
viability after the assays. 
As can be seen, the percentage of cells counted after the execution of the assays was 
never below 60%, and as such it can be considered that the techniques were performed 
correctly and the measurements obtained corresponded in fact to the labeled cells. 
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In both figures though, the standard deviation values can be quite high. However, one 
have to keep in mind that the counting method is very subjective, highly depending on the 
operator, the equipment used, and a number of other variables impossible to control, which 
makes this a not very precise assay. Nonetheless, it is reliable enough to guarantee that the 
techniques were correctly performed. 
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Chapter 5  
Conclusions 
Size measurements confirmed that the models were prepared as intended, with liposome 
diameters being close to 100 nm. Neither drug seemed to affect liposome size. Zeta potential 
confirmed that normal model membranes had a surface charge close to neutral and tumoral 
model membranes were slightly negatively charged, which is consistent with what happens 
naturally. Increase in drug concentration made the potential less negative, meaning that the 
drug, positively charged at the pH used, was most likely interacting with the membrane. This 
is consistent with what is found in literature since the mechanism of action of both drugs 
involves intercalating the DNA molecule, and to access the DNA the drug has to have the 
ability to cross the membrane, so a drug-membrane interaction needs to occur [7]. 
Kp determination showed that the two drugs, although very similar in structure, partition 
very differently into the different mimetic systems. The highest Kp is found for the normal 
model, since this is the simplest and therefore most homogeneous one, composed of only one 
fluid lipid that creates a quite porous membrane, which is confirmed by the fact that the 
normal model presents the lowest phase transition temperatures of all models studied. 
Partition for the two drugs decreases with the presence of cholesterol in the membrane for 
normal models, but the opposite occurs for the tumoral models. Doxorubicin partitions more 
than daunorubicin for all models except tumoral with cholesterol. 
In both models without cholesterol, daunorubicin appears to localize between the acyl 
chains of phospholipids in the membrane while still interacting through electrostatic 
interactions with the polar heads, so it appears to locate at an intermediate region. A 
previous study showed that doxorubicin’s location in DPPC models was between the acyl 
chains of the phospholipids [88]. This is an interesting finding – since doxorubicin is more 
hydrophobic, it locates in hydrophobic regions of the bilayer, while in our study we have 
found that daunorubicin, which is less hydrophobic, is able to locate between the acyl chains 
and also interact with the polar headgroup of phospholipids, which makes sense. 
Using the tumoral cells results were obtained that indicate that the drug located at a 
more superficial level, and the impairment in the entrance into the membrane might be 
related to the high complexity and variety of its components. As such, some of similarities 
could be drawn between the tumoral models and the tumoral cells, which leads to believe 
that the formulations designed in this study did a quite good job at mimicking the cell 
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membranes they intended to mimic, which is very good considering this is a first step toward 
that objective. Also very interesting is to keep in mind that we were able to prove or confirm 
that membrane location can be assessed for cells through the same techniques employed for 
liposomes and that enlightening results can be obtained.  
In terms of fluidity, the normal model with cholesterol appears to be the most rigid of all 
and remains unchanged by the drugs, while the normal model is highly fluid. Contrarily to 
what was expected, the tumoral model with cholesterol becomes more fluid at the interfacial 
or more superficial region (TMA-DPH region) with the addition of either drug fluid with the 
presence of drug, which does not happen in the tumoral model without cholesterol. The same 
is curiously found for the profiles obtained using the cells under the effect of daunorubicin, 
which further supports that the models were very good cell membrane simulators. Also, it is 
very important that profiles of anisotropy along a range of temperatures were obtaines for 
cells, which had not been described before either, and would be thought to be impossible 
due to the cells complexity. 
It is also important to note that, looking at the viability results, the techniques could be 
performed while maintained a high rate of live cells in the sample (always above 60%), which 
proves that these methodologies can continue to be employed in this sense. 
To justify the obtained results, the cholesterol might be forming microdomains with some 
of the lipids of the tumoral model, increasing the rigidity of the membrane in the areas those 
domains begin to exist, but making the remaining portion of the membrane more permeable. 
This hypothesis makes sense considering the higher partition into the tumoral with 
cholesterol model which is the most interesting one at a physiological level since it was 
designed to mimic the tumoral cell membrane. A high partition of both drugs into the 
membrane as well as the increase in membrane fluidity for this model is according to the fact 
that they are some of the most effective drugs in the treatment of cancer since a high 
partition indicates high interaction with the membrane and probably higher ability to cross 
the membrane. The fact that doxorubicin has higher partition coefficient for all the mimetic 
systems except the tumoral with cholesterol one can justify the higher severity of its side 
effects in comparison to daunorubicin [119-121]. 
Overall it appears that the models projected were a good example to study the 
interactions between these two drugs and the membrane, providing some enticing and 
clarifying information. The membrane location and fluidity studies using cells are a complete 
novelty in this field that produced interesting results, that to a certain degree allow 
validating the tumoral models in this study and can help in the future to develop even more 
accurate models that can be revolutionary to the world of membrane biophysics as we know 
it now. 
This study and follow-up work can be a big step towards the validation of liposomes as 
models for cell membranes, and in the future allow the facilitation of drug-interaction 
studies. Possible future applications would involve not only the use in research but the 
introduction of the models at an industrial level for an easier, less expensive and quicker 
development of new drugs or delivery systems for the treatment of several diseases that are 
more efficient and with fewer side effects. 
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Chapter 6  
Future Work 
In the future, membrane location studies should also be performed using the four 
liposome models and the tumoral cells for the drug doxorubicin. 
The same studies (membrane location and anisotropy) should also be performed on MCF 
10A cells, which are cells from normal breast gland tissue and, as such, the normal 
counterpart of the tumoral cells used. These studies would not only allow a comparison with 
the results obtained for the normal models with intent to improve them but also allow a 
comparison of the behaviour of the drugs in normal and tumoral biomembranes. 
It would also be interesting to determine the partition coefficient using both lines of cells 
(MDA-MB-231, tumoral, and MCF 10A, normal), which would be useful to compare with the 
findings from the other techniques. For that purpose, a protocol should be designed, since at 
the moment there is no protocol that confirms the possibility of use of the derivative 
spectrophotometry to determine the Kp using cells. 
Further ahead, it would be important to perform all of these studies in other tumoral and 
normal cell lines, since the effect of drugs varies from cell type to cell type, not only due to 
their cell membrane but also due to internal molecular processes that differ depending on 
the tissue.  
After the execution of these studies, we would be equipped to draw conclusions that 
would allow the alteration of the models in this study to further resemble the actual 
biomembranes. Eventually, with the knowledge acquired, validation of the models could be 
performed and there would henceforth be a model membrane for breast adenocarcinoma. 
With further research there could be in the future the development of models for several 
cancer types or even several diseases other than cancer. This could then allow the study of 
not only drug-membrane interactions, but also of the effect of proteins that exist inserted or 
anchored to the biomembranes using the models created, which is another very enticing and 
essential line of work.  
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Chapter 8  
Annexes 
Annex I Plotted results of the static, dynamic and Stern-Volmer constants determined using a 
regular spectrofluorimeter (left) and a plate-reading spectrofluorimeter (right. These 
constants were determined for all four models plus the tumoral cells MDA-MB-231 under the 
effect of daunorubicin for the two probes, DPH and TMA-DPH. 
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Annex II Static, dynamic and Stern-Volmer constants (Ks, KD, KSV respectively) obtained for 
the four models designed for this study plus the tumoral cells MDA-MD-231, for the two 
probes, DPH and TMA-DPH. 
  
Probes KD KS KSV 
Fluorimeter 
Normal 
DPH 24660 88583 113243 
TMA-DPH 52170 ± 4385 347275 ± 7187 399445 ± 11572 
Normal 
with 
Cholesterol 
DPH 6502 51592 58094 
TMA-DPH 7137 ± 842 55916 ± 6996 63053 ± 6154 
Tumoral 
DPH 85352 ± 530 235949 ± 2649 321301 ± 2120 
TMA-DPH 53499 ± 5592 240108 ± 7276 293607 ± 1684 
Tumoral 
with  
Cholesterol 
DPH 44208 ± 629 187358 ± 4229 231567 ± 3600 
TMA-DPH 56812 ± 2631 76351 ± 1528 133164 ± 4159 
Plate 
Reader 
Normal 
DPH 24 660 88583 113243 
TMA-DPH 52170 ± 4385 266284 ± 25731 318454 ± 21346 
Normal 
with 
Cholesterol 
DPH 6389 ± 161 54851 ± 3990 61240 ± 4151 
TMA-DPH 7137 ± 842 40624 ± 1995 47762 ± 2837 
Tumoral 
DPH 85352 ± 530 222465 ± 14996 307817 ± 15526 
TMA-DPH 53499 ± 5592 204264 ± 58087 257763 ± 63679 
Tumoral 
with  
Cholesterol 
DPH 44208 ± 629 142125 ± 5135 186333 ± 5764 
TMA-DPH 56812 ± 2631 82106 ± 2084 138918 ± 6798 
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Annex III Bimolecular constant (Kq) obtained for the four models designed for this study plus 
the tumoral cells MDA-MD-231, for the two probes, DPH and TMA-DPH. plus the tumoral cells 
MDA-MD-231, for the two probes, DPH and TMA-DPH. 
Method Model Probe Kq (x 1E+13) 
Fluorimeter 
Normal 
DPH 1.4 ± 0.6 
TMA-DPH 9.68 ± 0.05 
Normal with Cholesterol 
DPH 0.6 
TMA-DPH 0.85 ± 0.07 
Tumoral 
DPH 3.9 ± 0.1 
TMA-DPH 8.01 ± 0.09 
Tumoral with  
Cholesterol 
DPH 2.49 ± 0.03 
TMA-DPH 2.21 ± 0.08 
Plate 
Reader 
Normal 
DPH 1.3 
TMA-DPH 7.7 ± 0.7 
Normal with Cholesterol 
DPH 0.60 ± 0.04 
TMA-DPH 0.65 ± 0.05 
Tumoral 
DPH 3.7 ± 0.3 
TMA-DPH 7 ± 2 
Tumoral with  
Cholesterol 
DPH 2.01 ± 0.07 
TMA-DPH 2.3 ± 0.1 
Tumoral Cells 
DPH 0.48 ± 0.01 
TMA-DPH 3.8 ± 0.5 
 
